Double-stranded rna (dsRNA) induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as rna interference (RNAi). Using a Drosophila in vitro system, we demonstrate that 19–23 nt short rna fragments are the sequence-specific mediators of RNAi. The short interfering RNAs (siRNAs) are generated by an RNase III-like processing reaction from long dsRNA. Chemically synthesized siRNA duplexes with overhanging 3′ ends mediate efficient target rna cleavage in the lysate, and the cleavage site is located near the center of the region spanned by the guiding siRNA. Furthermore, we provide evidence that the direction of dsRNA processing determines whether sense or antisense target rna can be cleaved by the produced siRNP complex.
|
7. An improved method for preparing a double stranded rna molecule for mediating the cleavage of an mrna in a mammalian cell, comprising synthesizing a double stranded rna molecule,
wherein the improvement comprises synthesizing a double stranded rna molecule having a double stranded region of 16–24 nucleotides in length and one or more 3′ overhang regions of 1–3 nucleotides in length.
14. An improved method for preparing a double stranded rna molecule for mediating the cleavage of an mrna in a mammalian cell, comprising synthesizing a double stranded rna molecule,
wherein the improvement comprises synthesizing a double stranded rna molecule having a double stranded region of 16–22 nucleotides in length and one or more 3′ overhang regions of 1–3 nucleotides in length.
8. An improved method for preparing a double stranded rna molecule for mediating the cleavage of an mrna in a mammalian cell, comprising preparing and isolating a double stranded rna molecule,
wherein the improvement comprises preparing and isolating a double stranded rna molecule having a double stranded region of 16–24 nucleotides in length and one or more 3′ overhang regions of 1–3 nucleotides in length.
15. An improved method for preparing a double stranded rna molecule for mediating the cleavage of an mrna in a mammalian cell, comprising preparing and isolating a double stranded rna molecule,
wherein the improvement comprises preparing and isolating a double stranded rna molecule having a double stranded region of 16–22 nucleotides in length and one or more 3′ overhang regions of 1–3 nucleotides in length.
1. A method for preparing a double stranded rna molecule which mediates the cleavage of an mrna in a mammalian cell, comprising
(a) synthesizing two rna strands each having a length from 19–25 nucleotides, and
(b) combining the synthesized rna strands under conditions suitable to form a double stranded rna molecule, wherein said double stranded rna molecule has a double stranded region of 14–24 nucleotides in length and one or two 3′ overhang regions of 1–5 nucleotides in length.
9. A method for preparing a double stranded rna molecule which mediates the cleavage of an mrna in a mammalian cell, comprising
(a) synthesizing two rna strands each having a length from 19–23 nucleotides, and
(b) combining the synthesized rna strands under conditions suitable to form a double stranded rna molecule, wherein said double stranded rna molecule has a double stranded region of 14–22 nucleotides in length and one or two 3′ overhang regions of 1–5 nucleotides in length.
6. A method for preparing a double stranded rna molecule which mediates the cleavage of a target mrna in a mammalian cell, comprising
(a) selecting a target mammalian mrna sequence or target gene sequence,
(b) synthesizing a first rna strand having a length from 19–25 nucleotides, wherein said first rna strand is complementary to contiguous nucleotides in said target mammalian mrna or said target gene sequence
(c) synthesizing a second rna strand having a length from 19–25 nucleotides, wherein said second rna strand is complementary to 14–24 nucleotides from said first rna strand, and
(d) combining the first and second rna strands under conditions suitable to form a double stranded rna molecule, wherein said double stranded rna molecule has a double stranded region of 14–24 nucleotides in length and one or two 3′ overhang regions of 1–5 nucleotides in length.
13. A method for preparing a double stranded rna molecule which mediates the cleavage of a target mrna in a mammalian cell, comprising
(a) selecting a target mammalian mrna sequence or target gene sequence,
(b) synthesizing a first rna strand having a length from 19–23 nucleotides, wherein said first rna strand is complementary to contiguous nucleotides in said target mammalian mrna or said target gene sequence
(c) synthesizing a second rna strand having a length from 19–23 nucleotides, wherein said second rna strand is complementary to 16–22 nucleotides from said first rna strand, and
(d) combining the first and second rna strands under conditions suitable to form a double stranded rna molecule, wherein said double stranded rna molecule has a double stranded region of 16–22 nucleotides in length and one or two 3′ overhang regions of 1–5 nucleotides in length.
2. The method according to
|
This application is a divisional of Ser. No. 10/433,050 filed Jul. 26, 2004, which is a 35 USC § 371 National Phase Entry Application from PCT/EP01/13968, filed Nov. 29, 2001, and designating the U.S., which claims the benefit of provisional application No. 60/279,661, Mar. 30, 2001. All of these applications are incorporated herein by reference.
The present invention relates to sequence and structural features of double-stranded (ds)RNA molecules required to mediate target-specific nucleic acid modifications such as RNA-interference and/or DNA methylation.
The term “RNA interference” (RNAi) was coined after the discovery that injection of dsRNA into the nematode C. elegans leads to specific silencing of genes highly homologous in sequence to the delivered dsRNA (Fire et al., 1998). RNAi was subsequently also observed in insects, frogs (Oelgeschlager et al., 2000), and other animals including mice (Svoboda et al., 2000; Wianny and Zernicka-Goetz, 2000) and is likely to also exist in human. RNAi is closely linked to the post-transcriptional gene-silencing (PTGS) mechanism of co-suppression in plants and quelling in fungi (Catalanotto et al., 2000; Cogoni and Macino, 1999; Dalmay et al., 2000, Ketting and Plasterk, 2000; Mourrain et al., 2000; Smardon et al., 2000) and some components of the RNAi machinery are also necessary for post-transcriptional silencing by co-suppression (Catalanotto et al., 2000; Dernburg et al., 2000; Ketting and Plasterk, 2000). The topic has also been reviewed recently (Bass, 2000; Bosher and Labouesse, 2000; Fire, 1999; Plasterk and. Ketting, 2000; Sharp, 1999; Sijen and Kooter, 2000), see also the entire issue of Plant Molecular Biology, vol. 43, issue 2/3, (2000).
In plants, in addition to PTGS, introduced transgenes can also lead to transcriptional gene silencing via RNA-directed DNA methylation of cytosines (see references in Wassenegger, 2000). Genomic targets as short as 30 bp are methylated in plants in an RNA-directed manner (Pelissier, 2000). DNA methylation is also present in mammals.
The natural function of RNAi and co-suppression appears to be protection of the genome against invasion by mobile genetic elements such as retrotransposons and viruses which produce aberrant RNA or dsRNA in the host cell when they become active (Jensen et al, 1999; Ketting et al., 1999; Ratcliff et al., 1999; Tabara et al., 1999). Specific mRNA degradation prevents transposon and virus replication although some viruses are able to overcome or prevent this process by expressing proteins that suppress PTGS (Lucy et al.; 2000; Voinnet et al., 2000).
DsRNA triggers the specific degradation of homologous RNAs only within the region of identity with the dsRNA (Zamore et al., 2000). The dsRNA is processed to 21–23 nt RNA fragments and the target RNA cleavage sites are regularly spaced 21–23 nt apart. It has therefore been suggested that the 21–23 nt fragments are the guide RNAs for target recognition (Zamore et al., 2000). These short RNAs were also detected in extracts prepared from D. melanogaster Schneider 2 cells which were transfected with dsRNA prior to cell lysis (Hammond et al. 2000), however, the fractions that displayed sequence-specific nuclease activity also contained a large fraction of residual dsRNA. The role of the 21–23 nt fragments in guiding mRNA cleavage is further supported by the observation that 21–23 nt fragments isolated from processed dsRNA are able, to some extent, to mediate specific mRNA degradation (Zamore et al., 2000). RNA molecules of similar size also accumulate in plant tissue that exhibits PTGS (Hamilton and Baulcombe, 1999).
Here, we use the established Drosophila in vitro system (Tuschl et al., 1999; Zamore et al., 2000) to further explore the mechanism of RNAi. We demonstrate that short 21 and 22 nt RNAs, when base-paired with 3′ overhanging ends, act as the guide RNAs for sequence-specific mRNA degradation. Short 30 bp dsRNAs are unable to mediate RNAi in this system because they are no longer processed to 21 and 22 nt RNAs. Furthermore, we defined the target RNA cleavage sites relative to the 21 and 22 nt short interfering RNAs (siRNAs) and provide evidence that the direction of dsRNA processing determines whether a sense or an antisense target RNA can be cleaved by the produced siRNP endonuclease complex. Further, the siRNAs may also be important tools for transcriptional modulating, e.g. silencing of mammalian genes by guiding DNA methylation.
Further experiments in human in vivo cell culture systems (HeLa cells) show that double-stranded RNA molecules having a length of preferably from 19–25 nucleotides have RNAi activity. Thus, in contrast to the results from Drosophila also 24 and 25 nt long double-stranded RNA molecules are efficient for RNAi.
The object underlying the present invention is to provide novel agents capable of mediating target-specific RNA interference or other target-specific nucleic acid modifications such as DNA methylation, said agents having an improved efficacy and safety compared to prior art agents.
The solution of this problem is provided by an isolated double-stranded RNA molecule, wherein each RNA strand has a length from 19–25, particularly from 19–23 nucleotides, wherein said RNA molecule is capable of mediating target-specific nucleic acid modifications, particularly RNA interference and/or DNA methylation. Preferably at least one strand has a 3′-overhang from 1–5 nucleotides, more preferably from 1–3 nucleotides and most preferably 2 nucleotides. The other strand may be blunt-ended or has up to 6 nucleotides 3′ overhang. Also, if both strands of the dsRNA are exactly 21 or 22 nt, it is possible to observe some RNA interference when both ends are blunt (0 nt overhang). The RNA molecule is preferably a synthetic RNA molecule which is substantially free from contaminants occurring in cell extracts, e.g. from Drosophila embryos. Further, the RNA molecule is preferably substantially free from any non-target-specific contaminants, particularly non-target-specific RNA molecules e.g. from contaminants occuring in cell extracts.
Further, the invention relates to the use of isolated double-stranded RNA molecules, wherein each RNA strand has a length from 19–25 nucleotides, for mediating, target-specific nucleic acid modifications, particularly RNAi, in mammalian cells, particularly in human cells.
Surprisingly, it was found that synthetic short double-stranded RNA molecules particularly with overhanging 3′-ends are sequence-specific mediators of RNAi and mediate efficient target-RNA cleavage, wherein the cleavage site is located near the center of the region spanned by the guiding short RNA.
Preferably, each strand of the RNA molecule has a length from 20–22 nucleotides (or 20–25 nucleotides in mammalian cells), wherein the length of each strand May be the same or different. Preferably, the length of the 3′-overhang reaches from 1–3 nucleotides, wherein the length of the overhang may be the same or different for each strand. The RNA-strands preferably have 3′-hydroxyl groups. The 5′-terminus preferably comprises a phosphate, diphosphate, triphosphate or hydroxyl group. The most effective dsRNAs are composed of two 21 nt strands which are paired such that 1–3, particularly 2 nt 3′ overhangs are present on both ends of the dsRNA.
The target RNA cleavage reaction guided by siRNAs is highly sequence-specific. However, not all positions of a siRNA contribute equally to target recognition. Mismatches in the center of the siRNA duplex are most critical and essentially abolish target RNA cleavage. In contrast, the 3′ nucleotide of the siRNA strand (e.g. position 21) that is complementary to the single-stranded target RNA, does not contribute to specificity of the target recognition. Further, the sequence of the unpaired 2-nt 3′ overhang of the siRNA strand with the same polarity as the target RNA is not critical for target RNA cleavage as only the antisense siRNA strand guides target recognition. Thus, from the single-stranded overhanging nucleotides only the penultimate position of the antisense siRNA (e.g. position 20) needs to match the targeted sense mRNA.
Surprisingly, the double-stranded RNA molecules of the present invention exhibit a high in vivo stability in serum or in growth medium for cell cultures. In order to further enhance the stability, the 3′-overhangs may be stablized against degradation, e.g. they may be selected such that they consist of purine nucleotides, particularly adenosine or guanosine nucleotides. Alternatively, substitution of pyrimidine nucleotides by modified analogues, e.g. substitution of uridine 2 nt 3′ overhangs by 2′-deoxythymidine is tolerated and does not affect the efficiency of RNA interference. The absence of a 2′ hydroxyl significantly enhances the nuclease resistance of the overhang in tissue culture medium.
In an especially preferred embodiment of the present invention the RNA molecule may contain at least one modified nucleotide analogue. The nucleotide analogues may be located at positions where the target-specific activity, e.g. the RNAi mediating activity is not substantially effected, e.g. in a region at the 5′-end and/or the 3′-end of the double-stranded RNA molecule. Particularly, the overhangs may be stabilized by incorporating modified nucleotide analogues.
Preferred nucleotide analogues are selected from sugar- or backbone-modified ribonucleotides. It should be noted, however, that also nucleobase-modified ribonucleotides, i.e. ribonucleotides, containing a non-naturally occurring nucleobase instead of a naturally occurring nucleobase such as uridines or cytidines modified at the 5-position, e.g. 5-(2-amino)propyl uridine, 5-bromo uridine; adenosines and guanosines modified at the 8-position, e.g. 8-bromo guanosine; deaza nucleotides, e.g. 7-deaza-adenosine; O- and N-alkylated nucleotides, e.g. N6-methyl adenosine are suitable. In preferred sugar-modified ribonucleotides the 2′ OH-group is replaced by a group selected from H, OR, R, halo, SH, SR, NH2, NHR, NR2 or CN, wherein R is C1–C6 alkyl, alkenyl or alkynyl and halo is F, Cl, Br or I. In preferred backbone-modified ribonucleotides the phosphoester group connecting to adjacent ribonucleotides is replaced by a modified group, e.g. of phosphothioate group. It should be noted that the above modifications may be combined.
The sequence of the double-stranded RNA molecule of the present invention has to have a sufficient identity to a nucleic acid target molecule in order to mediate target-specific RNAi and/or DNA methylation. Preferably, the sequence has an identity of at least 50%, particularly of at least 70% to the desired target molecule in the double-stranded portion of the RNA molecule. More preferably, the identity is at least 85% and most preferably 100% in the double-stranded portion of the RNA molecule. The identity of a double-stranded RNA molecule to a predetermined nucleic acid target molecule, e.g. an mRNA target molecule may be determined as follows:
wherein I is the identity in percent, n is the number of identical nucleotides in the double-stranded portion of the ds RNA and the target and L is the length of the sequence overlap of the double-stranded portion of the dsRNA and the target.
Alternatively, the identity of the double-stranded RNA molecule to the target sequence may also be defined including the 3′ overhang, particularly an overhang having a length from 1–3 nucleotides. In this case the sequence identity is preferably at least 50%, more preferably at least 70% and most preferably at least 85% to the target sequence. For example, the nucleotides from the 3′ overhang and up to 2 nucleotides from the 5′ and/or 3′ terminus of the double strand may be modified without significant loss of activity.
The double-stranded RNA molecule of the invention may be prepared by a method comprising the steps:
Methods of synthesizing RNA molecules are known in the art. In this context, it is particularly referred to chemical synthesis methods as described in Verma and Eckstein (1998).
The single-stranded RNAs can also be prepared by enzymatic transcription from synthetic DNA templates or from DNA plasmids isolated from recombinant bacteria. Typically, phage RNA polymerases are used such as T7, T3 or SP6 RNA polymerase (Milligan and Uhlenbeck (1989)).
A further aspect of the present invention relates to a method of mediating target-specific nucleic acid modifications, particularly RNA interference and/or DNA methylation in a cell or an organism comprising the steps:
Preferably the contacting step (a) comprises introducing the double-stranded RNA molecule into a target cell, e.g. an isolated target cell, e.g. in cell culture, a unicellular microorganism or a target cell or a plurality of target cells within a multicellular organism. More preferably, the introducing step comprises a carrier-mediated delivery, e.g. by liposomal carriers or by injection.
The method of the invention may be used for determining the function of a gene in a cell or an organism or even for modulating the function of a gene in a cell or an organism, being capable of mediating RNA interference. The cell is preferably a eukaryotic cell or a cell line, e.g. a plant cell or an animal cell, such as a mammalian cell, e.g. an embryonic cell, a pluripotent stem cell, a tumor cell, e.g. a teratocarcinoma cell or a virus-infected cell. The organism is preferably a eukaryotic organism, e.g. a plant or an animal, such as a mammal, particularly a human.
The target gene to which the RNA molecule of the invention is directed may be associated with a pathological condition. For example, the gene may be a pathogen-associated gene, e.g. a viral gene, a tumor-associated gene or an autoimmune disease-associated gene. The target gene may also be a heterologous gene expressed in a recombinant cell or a genetically altered organism. By determinating or modulating, particularly, inhibiting the function of such a gene valuable information and therapeutic benefits in the agricultural field or in the medicine or veterinary medicine field may be obtained.
The dsRNA is usually administered as a pharmaceutical composition. The administration may be carried out by known methods, wherein a nucleic acid is introduced into a desired target cell in vitro or in vivo. Commonly used gene transfer techniques include calcium phosphate, DEAE-dextran, electroporation and microinjection and viral methods (Graham, F. L. and van der Eb, A. J. (1973) Virol. 52, 456; McCutchan, J. H. and Pagano, J. S. (1968), J. Natl. Cancer Inst. 41, 351; Chu, G. et al (1987), Nucl. Acids Res. 15, 1311; Fraley, R. et al. (1980), J. Biol. Chem. 255, 10431; Capecchi, M. R. (1980), Cell 22, 479). A recent addition to this arsenal of techniques for the introduction of DNA into cells is the use of cationic liposomes (Feigner, P. L. et al. (1987), Proc. Natl. Acad. Sci USA 84, 7413). Commercially available cationic lipid formulations are e.g. Tfx 50 (Promega) or Lipofectamin2000 (Life Technologies).
Thus, the invention also relates to a pharmaceutical composition containing as an active agent at least one double-stranded RNA molecule as described above and a pharmaceutical carrier. The composition may be used for diagnostic and for therapeutic applications in human medicine or in veterinary medicine.
For diagnostic or therapeutic applications, the composition may be in form of a solution, e.g. an injectable solution, a cream, ointment, tablet, suspension or the like. The composition may be administered in any suitable way, e.g. by injection, by oral, topical, nasal, rectal application etc. The carrier may be any suitable pharmaceutical carrier. Preferably, a carrier is used, which is capable of increasing the efficacy of the RNA molecules to enter the target-cells. Suitable examples of such carriers are liposomes, particularly cationic liposomes. A further preferred administration method is injection.
A further preferred application of the RNAi method is a functional analysis of eukaryotic cells, or eukaryotic non-human organisms, preferably mammalian cells or organisms and most preferably human cells, e.g. cell lines such as HeLa or 293 or rodents, e.g. rats and mice. By transfection with suitable double-stranded RNA molecules which are homologous to a predetermined target gene or DNA molecules encoding a suitable double-stranded RNA molecule a specific knockout phenotype can be obtained in a target cell, e.g. in cell culture or in a target organism. Surprisingly it was found that the presence of short double-stranded RNA molecules does not result in an interferon response from the host cell or host organism.
Thus, a further subject matter of the invention is a eukaryotic cell or a eukaryotic non-human organism exhibiting a target gene-specific knockout phenotype comprising an at least partially deficient expression of at least one endogeneous target gene wherein said cell or organism is transfected with at least one double-stranded RNA molecule capable of inhibiting the expression of at least one endogeneous target gene or with a DNA encoding at least one double stranded RNA molecule capable of inhibiting the expression of at least one endogeneous target gene. It should be noted that the present invention allows a target-specific knockout of several different endogeneous genes due to the specificity of RNAi.
Gene-specific knockout phenotypes of cells or non-human organisms, particularly of human cells or non-human mammals may be used in analytic procedures, e.g. in the functional and/or phenotypical analysis of complex physiological processes such as analysis of gene expression profiles and/or proteomes. For example, one may prepare the knock-out phenotypes of human genes in cultured cells which are assumed to be regulators of alternative splicing processes. Among these genes are particularly the members of the SR splicing factor family, e.g. ASF/SF2, SC35, SRp20, SRp40 or SRp55. Further, the effect of SR proteins on the mRNA profiles of predetermined alternatively spliced genes such as CD44 may be analysed. Preferably the analysis is carried out by high-throughput methods using oligonucleotide based chips.
Using RNAi based knockout technologies, the expression of an endogeneous target gene may be inhibited in a target cell or a target organism. The endogeneous gene may be complemented by an exogeneous target nucleic acid coding for the target protein or a variant or mutated form of the target protein, e.g. a gene or a cDNA, which may optionally be fused to a further nucleic acid sequence encoding a detectable peptide or polypeptide, e.g. an affinity tag, particularly a multiple affinity tag. Variants or mutated forms of the target gene differ from the endogeneous target gene in that they encode a gene product which differs from the endogeneous gene product on the amino acid level by substitutions, insertions and/or deletions of single or multiple amino acids. The variants or mutated forms may have the same biological activity as the endogeneous target gene. On the other hand, the variant or mutated target gene may also have a biological activity, which differs from the biological activity of the endogeneous target gene, e.g. a partially deleted activity, a completely deleted activity, an enhanced activity etc.
The complementation may be accomplished by coexpressing the polypeptide encoded by the exogeneous nucleic acid, e.g. a fusion protein comprising the target protein and the affinity tag and the double stranded RNA molecule for knocking out the endogeneous gene in the target cell. This coexpression may be accomplished by using a suitable expression vector expressing both the polypeptide encoded by the exogeneous nucleic acid, e.g. the tag-modified target protein and the double stranded RNA molecule or alternatively by using a combination of expression vectors. Proteins and protein complexes which are synthesized de novo in the target cell will contain the exogeneous gene product, e.g. the modified fusion protein. In order to avoid suppression of the exogeneous gene product expression by the RNAi duplex molecule, the nucleotide sequence encoding the exogeneous nucleic acid may be altered on the DNA level (with or without causing mutations on the amino acid level) in the part of the sequence which is homologous to the double stranded RNA molecule. Alternatively, the endogeneous target gene may be complemented by corresponding nucleotide sequences from other species, e.g. from mouse.
Preferred applications for the cell or organism of the invention is the analysis of gene expression profiles and/or proteomes. In an especially preferred embodiment an analysis of a variant or mutant form of one or several target proteins is carried out, wherein said variant or mutant forms are reintroduced into the cell or organism by an exogeneous target nucleic acid as described above. The combination of knockout of an endogeneous gene and rescue by using mutated, e.g. partially deleted exogeneous target has advantages compared to the use of a knockout cell. Further, this method is particularly suitable for identifying functional domains of the target protein. In a further preferred embodiment a comparison, e.g. of gene expression profiles and/or proteomes and/or phenotypic characteristics of at least two cells or organisms is carried out. These organisms are selected from:
The method and cell of the invention are also suitable in a procedure for identifying and/or characterizing pharmacological agents, e.g. identifying new pharmacological agents from a collection of test substances and/or characterizing mechanisms of action and/or side effects of known pharmacological agents.
Thus, the present invention also relates to a system for identifying and/or characterizing pharmacological agents acting on at least one target protein comprising:
Further, the system as described above preferably comprises:
Furthermore, the RNA knockout complementation method may be used for preparative purposes, e.g. for the affinity purification of proteins or protein complexes from eukaryotic cells, particularly mammalian cells and more particularly human cells. In this embodiment of the invention, the exogeneous target nucleic acid preferably codes for a target protein which is fused to an affinity tag.
The preparative method may be employed for the purification of high molecular weight protein complexes which preferably have a mass of ≧150 kD and more preferably of ≧500 kD and which optionally may contain nucleic acids such as RNA. Specific examples are the heterotrimeric protein complex consisting of the 20 kD, 60 kD and 90 kD proteins of the U4/U6 snRNP particle, the splicing factor SF3b from the 17S U2 snRNP consisting of 5 proteins having molecular weights of 14, 49, 120, 145 and 155 kD and the 25S U4/U6/U5 tri-snRNP particle containing the U4, U5 and U6 snRNA molecules and about 30 proteins, which has a molecular weight of about 1.7 MD.
This method is suitable for functional proteome analysis in mammalian cells, particularly human cells.
Further, the present invention is explained in more detail in the following figures and examples.
(A) Graphic representation of dsRNAs used for targeting Pp-luc mRNA. Three series of blunt-ended dsRNAs covering a range of 29 to 504 bp were prepared. The position of the first nucleotide of the sense strand of the dsRNA is indicated relative to the start codon of Pp-luc mRNA (p1). (B) RNA interference assay (Tuschl et al., 1999). Ratios of target Pp-luc to control Rr-luc activity were normalized to a buffer control (black bar). DsRNAs (5 nM) were preincubated in Drosophila lysate for 15 min at 25° C. prior to the addition of 7-methyl-guanosine-capped Pp-luc and Rr-luc mRNAs (˜50 pM). The incubation was continued for another hour and then analyzed by the dual luciferase assay (Promega). The data are the average from at least four independent experiments±standard deviation.
Time course of 21–23 mer formation from processing of internally 32P-labeled dsRNAs (5 nM) in the Drosophila lysate. The length and source of the dsRNA are indicated. An RNA size marker (M) has been loaded in the left lane and the fragment sizes are indicated. Double bands at time zero are due to incompletely denatured dsRNA.
(A) Denaturing gel electrophoreses of the stable 5′ cleavage products produced by 1 h incubation of 10 nM sense or antisense RNA 32P-labeled at the cap with 10 nM dsRNAs of the p133 series in Drosophila lysate. Length markers were generated by partial nuclease T1 digestion and partial alkaline hydrolysis (OH) of the cap-labeled target RNA. The regions targeted by the dsRNAs are indicated as black bars on both sides. The 20–23 nt spacing between the predominant cleavage sites for the 111 bp long dsRNA is shown. The horizontal arrow indicates unspecific cleavage not due to RNAi. (B) Position of the cleavage sites on sense and antisense target RNAs. The sequences of the capped 177 nt sense and 180 nt antisense target RNAs are represented in antiparallel orientation such that complementary sequence are opposing each other. The region targeted by the different dsRNAs are indicated by differently colored bars positioned between sense and antisense target sequences. Cleavage sites are indicated by circles: large circle for strong cleavage, small circle for weak cleavage. The 32P-radiolabeled phosphate group is marked by an asterisk.
(A) Sequences of ˜21 nt RNAs after dsRNA processing. The ˜21 nt RNA fragments generated by dsRNA processing were directionally cloned and sequenced. Oligoribonucleotides originating from the sense strand of the dsRNA are indicated as blue lines, those originating from the antisense strand as red lines. Thick bars are used if the same sequence was present in multiple clones, the number at the right indicating the frequency. The target RNA cleavage sites mediated by the dsRNA are indicated as orange circles, large circle for strong cleavage, small circle for weak cleavage (see
(A) Graphic representation of control 52 bp dsRNA and synthetic 21 and 22 nt dsRNAs. The sense strand of 21 and 22 nt short interfering RNAs (siRNAs) is shown blue, the antisense strand in red. The sequences of the siRNAs were derived from the cloned fragments of 52 and 111 bp dsRNAs (
(A) Graphic representation of 52 bp dsRNA constructs. The 3′ extensions of sense and antisense strand are indicated in blue and red, respectively. The observed cleavage sites on the target RNAs are represented as orange circles analogous to
RNAi is predicted to begin with processing of dsRNA (sense strand in black, antisense strand in red) to predominantly 21 and 22 nt short interfering RNAs (siRNAs). Short overhanging 3′ nucleotides, if present on the dsRNA, may be beneficial for processing of short dsRNAs. The dsRNA-processing proteins, which remain to be characterized, are represented as green and blue ovals, and assembled on the dsRNA in asymmetric fashion. In our model, this is illustrated by binding of a hypothetical blue protein or protein domain with the siRNA strand in 3′ to 5′ direction while the hypothetical green protein or protein domain is always bound to the opposing siRNA strand. These proteins or a subset remain associated with the siRNA duplex and preserve its orientation as determined by the direction of the dsRNA processing reaction. Only the siRNA sequence associated with the blue protein is able to guide target RNA cleavage. The endonuclease complex is referred to as small interfering ribonucleoprotein complex or siRNP. It is presumed here, that the endonuclease that cleaves the dsRNA may also cleave the target RNA, probably by temporarily displacing the passive siRNA strand not used for target recognition. The target RNA is then cleaved in the center of the region recognized by the sequence-complementary guide siRNA.
(a) The firefly (Pp-luc) and sea pansy (Rr-luc) luciferase reporter gene regions from plasmids pGL2-Control, pGL-3-Control and pRL-TK (Promega) are illustrated. SV40 regulatory elements, the HSV thymidine kinase promoter and two introns (lines) are indicated. The sequence of GL3 luciferase is 95% identical to GL2, but RL is completely unrelated to both. Luciferase expression from pGL2 is approx. 10-fold lower than from pGL3 in transfected mammalian cells. The region targeted by the siRNA duplexes is indicated as black bar below the coding region of the luciferase genes. (b) The sense (top) and antisense (bottom) sequences of the siRNA duplexes targeting GL2, GL3 and RL luciferase are shown. The GL2 and GL3 siRNA duplexes differ by only 3 single nucleotide substitutions (boxed in gray). As unspecific control, a duplex with the inverted GL2 sequence, invGL2, was synthesized. The 2 nt 3′ overhang of 2′-deoxythymidine is indicated as TT; uGL2 is similar to GL2 siRNA but contains ribo-uridine 3′ overhangs.
Ratios of target control luciferase were normalized to a buffer control (bu, black bars); gray bars indicate ratios of Photinus pyralis (Pp-luc) GL2 or GL3 luciferase to Renilla reniformis (Rr-luc) RL luciferase (left axis), white bars indicate RL to GL2 or GL3 ratios: (right axis). Panels a, c, e, g and i describe experiments performed with the combination of pGL2-Control and pRL-TK reporter plasmids, panels b, d, f, h and j with pGL3-Control and pRL-TK reporter plasmids. The cell line used for the interference experiment is indicated at the top of each plot. The ratios of Pp-luc/Rr-luc for the buffer control (bu) varied between 0.5 and 10 for pGL2/pRL and between 0.03 and 1 for pGL3/pRL, respectively, before normalization and between the various cell lines tested. The plotted data were averaged from three independent experiments±S.D.
The exact length of the long dsRNAs is indicated below the bars. Panels a, c and e describe experiments performed with pGL2-Control and pRL-TK reporter plasmids, panels b, d and f with pGL3-Control and pRL-TK reporter plasmids. The data were averaged from two in dependent experiments±S.D. (a), (b) Absolute Pp-luc expression, plotted in arbitrary luminescence units. (c), (d) Rr-luc expression, plotted in arbitrary luminescence units. (e), (f) Ratios of normalized target to control luciferase. The ratios of luciferase activity for siRNA duplexes were normalized to a buffer control (bu, black bars); the luminescence ratios for 50 or 500 bp dsRNAs were normalized to the respective ratios observed for 50 and 500 bp dsRNA from humanized GFP (hG, black bars). It should be noted that the overall differences in sequences between the 49 and 484 bp dsRNAs targeting GL2 and GL3 are not sufficient to confer specificity between GL2 and GL3 targets (43 nt uninterrupted identity in 49 bp segment, 239 nt longest uninterrupted identity in 484 bp segment).
[Part I] Outline of the experimental strategy. The capped and polyadenylated sense target mRNA is depicted and the relative positions of sense and antisense siRNAs are shown. Eight series of duplexes, according to the eight different antisense strands were prepared. The siRNA sequences and the number of overhanging nucleotides were changed in 1-nt steps. [Part I] Normalized relative luminescence of target luciferase (Photinus pyralis, Pp-luc) to control luciferase (Renilla renifomis, Rr-luc) in D. melanogaster embryo lysate in the presence of 5 nM blunt-ended dsRNAs. The luminescence ratios determined in the presence of dsRNA were normalized to the ratio obtained for a buffer control (bu, black bar). Normalized ratios less than 1 indicate specific interference. [Part I (C–D), Part II (E–G), Part III (H–J)] Normalized interference ratios for eight series of 21-nt siRNA duplexes. The sequences of siRNA duplexes are depicted above the bar graphs. Each panel shows the interference ratio for a set of duplexes formed with a given antisense guide siRNA and 5 different sense siRNAs. The number of overhanging nucleotides (3′ overhang, positive numbers; 5′ overhangs, negative numbers) is indicated on the x-axis. Data points were averaged from at least 3 independent experiments, error bars represent standard deviations.
(A) Graphic representation of the experiment. The 21-nt siRNA duplex is identical in sequence to the one shown in
The 2′-hydroxyl groups (OH) in the strands of siRNA duplexes were replaced by 2′-deoxy (d) or 2′-O-methyl (Me). 2-nt and 4-nt 2′-deoxy substitutions at the 3′-ends are indicated as 2-nt d and 4-nt d, respectively. Uridine residues were replaced by 2′-deoxy thymidine.
(A) Graphic representation of 32P (asterisk) cap-labelled sense and anti-sense target RNAs and siRNA duplexes. The position of sense and anti-sense target RNA cleavage is indicated by triangles on top and below the siRNA duplexes, respectively. (B) Mapping of target RNA cleavage sites. After 2 h incubation of 10 nM target with 100 nM siRNA duplex in D. melanogaster embryo lysate, the 5′ cap-labelled substrate and the 5′ cleavage products were resolved on sequencing gels. Length markers were generated by partial RNase T1 digestion (T1) and partial alkaline hydrolysis (OH—) of the target RNAs. The bold lines to the left of the images indicate the region covered by the siRNA strands 1 and 5 of the same orientation as the target.
(A, B) Graphic representation of the experimental strategy. The antisense siRNA was the same in all siRNA duplexes, but the sense strand was varied between 18 to 25 nt by changing the 3′ end (A) or 18 to 23 nt by changing the 5′ end (B). The position of sense and antisense target RNA cleavage is indicated by triangles on top and below the siRNA duplexes, respectively. (C, D) Analysis of target RNA cleavage using cap-labelled sense (top panel) or antisense (bottom panel) target RNAs. Only the cap-labelled 5′ cleavage products are shown. The sequences of the siRNA duplexes are indicated, and the length of the sense siRNA strands is marked on top of the panel. The control lane marked with a dash in panel (C) shows target RNA incubated in absence of siRNAs. Markers were as described in
The 2-nt 3′ overhang (NN, in gray) was changed in sequence and composition as indicated (T, 2′-deoxythymidine, dG, 2′-deoxyguanosine; asterisk, wild-type siRNA duplex). Normalized interference ratios were determined as described in
The sequences of the mismatched siRNA duplexes are shown, modified sequence segments or single nucleotides are underlayed in gray. The reference duplex (ref) and the siRNA duplexes 1 to 7 contain 2′-deoxythymidine 2-nt overhangs. The silencing efficiency of the thymidine-modified reference duplex was comparable to the wild-type sequence (
The siRNA duplexes were extended to the 3′ side of the sense siRNA (A) or the 5′ side of the sense siRNA (B). The siRNA duplex sequences and the respective interference ratios are indicated. For HeLa SS6 cells, siRNA duplexes (0.84 μg) targeting GL2 luciferase were transfected together with pGL2-Control and pRL-TK plasmids. For comparison, the in vitro RNAi activities of siRNA duplexes tested in D. melanogaster lysate are indicated.
RNA Interference Mediated by Small Synthetic RNAs
1.1. Experimental Procedures
1.1.1 In Vitro RNAi
In vitro RNAi and lysate preparations were performed as described previously (Tuschl et al., 1999; Zamore et al., 2000). It is critical to use freshly dissolved creatine kinase (Roche) for optimal ATP regeneration. The RNAi translation assays (
1.1.2 RNA Synthesis
Standard procedures were used for in vitro transcription of RNA from PCR templates carrying T7 or SP6 promoter sequences, see for example (Tuschl et al., 1998). Synthetic RNA was prepared using Expedite RNA phosphoramidites (Proligo). The 3′ adapter oligonucleotide was synthesized using dimethoxytrityl-1,4-benzenedimethanol-succinyl-aminopropyl-CPG. The oligoribonucleotides were deprotected in 3 ml of 32% ammonia/ethanol (3/1) for 4 h at 55° C. (Expedite RNA) or 16 h at 55° C. (3′ and 5′ adapter DNA/RNA chimeric oligonucleotides) and then desilylated and gel-purified as described previously (Tuschl et al., 1993). RNA transcripts for dsRNA preparation including long 3′ overhangs were generated from PCR templates that contained a T7 promoter in sense and an SP6 promoter in antisense direction. The transcription template for sense and antisense target RNA was PCR-amplified with GCGTAATACGACTCACTATAGAACAATTGCTTTTACAG (bold, T7 promoter) [SEQ ID NO: 1] as 5′ primer and ATTTAGGTGACACTATAGGCATAAAGAATTGAAGA (bold, SP6 promoter) [SEQ ID NO:2] as 3′ primer and the linearized Pp-luc plasmid (pGEM-luc sequence) (Tuschl et al., 1999) as template; the T7-transcribed sense RNA was 177 nt long with the Pp-luc sequence between pos. 113–273 relative to the start codon and followed by 17 nt of the complement of the SP6 promoter sequence at the 3′ end. Transcripts for blunt-ended dsRNA formation were prepared by transcription from two different PCR products which only contained a single promoter sequence.
DsRNA annealing was carried out using a phenol/chloroform extraction. Equimolar concentration of sense and antisense RNA (50 nM to 10 μM, depending on the length and amount available) in 0.3 M NaOAc (pH 6) were incubated for 30 s at 90° C. and then extracted at room temperature with an equal volume of phenol/chloroform, and followed by a chloroform extraction to remove residual phenol. The resulting dsRNA was precipitated by addition of 2.5–3 volumes of ethanol. The pellet was dissolved in lysis buffer (100 mM KCl, 30 mM HEPES-KOH, pH 7.4, 2 mM Mg(OAc)2) and the quality of the dsRNA was verified by standard agarose gel electrophoreses in 1×TAE-buffer. The 52 bp dsRNAs with the 17 nt and 20 nt 3′ overhangs (
Transcription of internally 32P-radiolabeled RNA used for dsRNA preparation (
1.1.3 Cleavage Site Mapping
Standard RNAi reactions were performed by pre-incubating 10 nM dsRNA for 15 min followed by addition of 10 nM cap-labeled target RNA. The reaction was stopped after a further 2 h (
1.1.4 Cloning of ˜21 nt RNAs
The 21 nt RNAs were produced by incubation of radiolabeled dsRNA in Drosophila lysate in absence of target RNA (200 FI reaction, 1 h incubation, 50 nM dsP111, or 100 nM dsP52 or dsP39). The reaction mixture was subsequently treated with proteinase K (Tuschl et al., 1999) and the dsRNA-processing products were separated on a denaturing 15% polyacrylamide gel. A band, including a size range of at least 18 to 24 nt, was excised, eluted into 0.3 M NaCl overnight at 4° C. and in siliconized tubes. The RNA was recovered by ethanol-precipitation and dephosphorylated (30 FI reaction, 30 mm, 5000,10 U alkaline phosphatase, Roche). The reaction was stopped by phenol/chloroform extraction and the RNA was ethanol-precipitated. The 3′ adapter oligonucleotide (pUUUaaccgcatccttctcx: uppercase, RNA; lowercase, DNA; p, phosphate; x, 4-hydroxymethylbenzyl) [SEQ ID NO: 100] was then ligated to the dephosphorylated ˜21 nt RNA (20 FI reaction, 30 min, 37° C., 5 FM 3′ adapter, 50 mM Tris-HOI, pH 7.6, 10 mM MgCl2, 0.2 mM ATP, 0.1 mg/ml acetylated BSA, 15% DMSO, 25 U T4 RNA ligase, Amersham-Pharmacia) (Pan and Uhlenbeck, 1992). The ligation reaction was stopped by the addition of an equal volume of 8 M urea/50 mM EDTA stopmix and directly loaded on a 15% gel. Ligation yields were greater 50%. The ligation product was recovered from the gel and 5′-phosphorylated (20 FI reaction, 30 mm, 37° C., 2 mM ATP, 5 U T4 polynucleotide kinase, NEB). The phosphorylation reaction was stopped by phenol/chloroform extraction and RNA was recovered by ethanol-precipitation. Next, the 5′ adapter (tactaatacgactcactAAA: uppercase, RNA; lowercase, DNA) [SEQ ID NO: 101] was ligated to the phosphorylated ligation product as described above. The new ligation product was gel-purified and eluted from the gel slice in the presence of reverse transcription primer (GACTAGCTGGAATTCAAGGATGCGGTTAAA: bold, Eco RI site) [SEQ ID NO: 3] used as carrier. Reverse transcription (15 FI reaction, 30 min, 42° C., 150 U Superscript II reverse transcriptase, Life Technologies) was followed by PCR using as 5′ primer CAGCCAACGGAATTCATACGACTCACTAAA (bold, Eco RI site) [SEQ ID NO: 4 ] and the 3′ RT primer. The PCR product was purified by phenol/chloroform extraction and ethanol-precipitated. The PCR product was then digested with Eco RI (NEB) and concatamerized using T4 DNA ligase (high conc., NEB). Concatamers of a size range of 200 to 800 bp were separated on a low-melt agarose gel, recovered from the gel by a standard melting and phenol extraction procedure, and ethanol-precipitated. The unpaired ends were filled in by incubation with Taq polymerase under standard conditions for 15 mm at 72° C. and the DNA product was directly ligated into the pCR2.1-TOPO vector using the TOPO TA cloning kit (Invitrogen). Colonies were screened using PCR and M13–20 and M13 Reverse sequencing primers. PCR products were directly submitted for custom sequencing (Sequence Laboratories Göttingen GmbH, Germany). On average, four to five 21 mer sequences were obtained per clone.
1.1.5 2D-TLC Analysis
Nuclease P1 digestion of radiolabeled, gel-purified siRNAs and 2D-TLC was carried out as described (Zamore et al., 2000). Nuclease T2 digestion was performed in 10 μl reactions for 3 h at 50° C. in 10 mM ammonium acetate (pH 4.5) using 2 μg/μl carrier tRNA and 30 U ribonuclease T2 (Life Technologies). The migration of non-radioactive standards was determined by UV shadowing. The identity of nucleoside-3′,5′-disphosphates was confirmed by co-migration of the T2 digestion products with standards prepared by 5′-32P-phosphorylation of commercial nucleoside 3′-monophosphates using γ-32P-ATP and T4 polynucleotide kinase (data not shown).
1.2 Results and Discussion
1.2.1 Length Requirements for Processing of dsRNA to 21 and 22 nt RNA Fragments
Lysate prepared from D. melanogaster syncytial embryos recapitulates RNAi in vitro providing a novel tool for biochemical analysis of the mechanism of RNAi (Tuschl et al., 1999; Zamore et al., 2000). In vitro and in vivo analysis of the length requirements of dsRNA for RNAi has revealed that short dsRNA (<150 bp) are less effective than longer dsRNAs in degrading target mRNA (Caplen et al., 2000; Hammond et al., 2000; Ngo et al., 1998); Tuschl et al., 1999). The reasons for reduction in mRNA degrading efficiency are not understood. We therefore examined the precise length requirement of dsRNA for target RNA degradation under optimized conditions in the Drosophila lysate (Zamore et al., 2000). Several series of dsRNAs were synthesized and directed against firefly luciferase (Pp-luc) reporter RNA. The specific suppression of target RNA expression was monitored by the dual luciferase assay (Tuschl et al., 1999) (
It has been suggested that the 21–23 nt RNA fragments generated by processing of dsRNAs are the mediators of RNA interference and co-suppression (Hamilton and Baulcombe, 1999; Hammond et al., 2000; Zamore et al., 2000). We therefore analyzed the rate of 21–23 nt fragment formation for a subset of dsRNAs ranging in size between 501 to 29 bp. Formation of 21–23 nt fragments in Drosophila lysate (
1.2.2 39 bp dsRNA Mediates Target RNA Cleavage at a Single Site
Addition of dsRNA and 5′-capped target RNA to the Drosophila lysate results in sequence-specific degradation of the target RNA (Tuschl et al., 1999). The target mRNA is only cleaved within the region of identity with the dsRNA and many of the target cleavage sites were separated by 21–23 nt (Zamore et al., 2000). Thus, the number of cleavage sites for a given dsRNA was expected to roughly correspond to the length of the dsRNA divided by 21. We mapped the target cleavage sites on a sense and an antisense target RNA which was 5′ radiolabeled at the cap (Zamore et al., 2000) (
Consistent with the previous observation (Zamore et al., 2000), all target RNA cleavage sites were located within the region of identity to the dsRNA. The sense or the antisense traget was only cleaved once by 39 bp dsRNA. Each cleavage site was located 10 nt from the 5′ end of the region covered by the dsRNA (
Cleavage sites on sense and antisense target for the longer 111 bp dsRNA were much more frequent than anticipated and most of them appear in clusters separated by 20 to 23 nt (
1.2.3 dsRNA is Processed to 21 and 22 nt RNAs by an RNase III-Like Mechanism
In order to characterize the 21–23 nt RNA fragments we examined the 5′ and 3′ termini of the RNA fragments. Periodate oxidation of gel-purified 21–23 nt RNAs followed by β-elimination indicated the presence of a terminal 2′ and 3′ hydroxyl groups. The 21–23 mers were also responsive to alkaline phosphatase treatment indicating the presence of a 5′ terminal phosphate group. The presence of 5′ phosphate and 3′ hydroxyl termini suggests that the dsRNA could be processed by an enzymatic activity similar to E. coli RNase III (for reviews, see (Dunn, 1982; Nicholson, 1999; Robertson, 1990; Robertson, 1982)).
Directional cloning of 21–23 nt RNA fragments was performed by ligation of a 3′ and 5′ adapter oligonucleotide to the purified 21–23 mers using T4 RNA ligase. The ligation products were reverse transcribed, PCR-amplified, concatamerized, cloned, and sequenced. Over 220 short RNAs were sequenced from dsRNA processing reactions of the 39, 52 and 111 bp dsRNAs (
The ˜21 nt RNAs appear in clustered groups (
The ˜21mer clusters for the 52 bp and 111 bp dsRNA are less well defined when compared to the 39 bp dsRNA. The clusters are spread over regions of 25 to 30 nt most likely representing several distinct subpopulations of ˜21 nt duplexes and therefore guiding target cleavage at several nearby sites. These cleavage regions are still predominantly separated by 20 to 23 nt intervals. The rules determining how regular dsRNA can be processed to ˜21 nt fragments are not yet understood, but it was previously observed that the approx. 21–23 nt spacing of cleavage sites could be altered by a run of uridines (Zamore et al., 2000). The specificity of dsRNA cleavage by E. coli RNase III appears to be mainly controlled by antideterminants, i.e. excluding some specific base-pairs at given positions relative to the cleavage site (Zhang and Nicholson, 1997).
To test whether sugar-, base- or cap-modification were present in processed ˜21 nt RNA fragments, we incubated radiolabeled 505 bp Pp-luc dsRNA in lysate for 1 h, isolated the ˜21 nt products, and digested it with P1 or T2 nuclease to mononucleotides. The nucleotide mixture was then analyzed by 2D thin-layer chromatography (
1.2.4 Synthetic 21 and 22 nt RNAs Mediate Target RNA Cleavage
Analysis of the products of dsRNA processing indicated that the ˜21 nt fragments are generated by a reaction with all the characteristics of an RNase III cleavage reaction (Dunn, 1982; Nicholson, 1999; Robertson, 1990; Robertson, 1982). RNase III makes two staggered cuts in both strands of the dsRNA, leaving a 3′ overhang of about 2 nt. We chemically synthesized 21 and 22 nt RNAs, identical in sequence to some of the cloned ˜21 nt fragments, and tested them for their ability to mediate target RNA degradation (
In contrast to 29 or 30 bp dsRNAs that did not mediate RNAi, the 21 and 22 nt dsRNAs with overhanging 3′ ends of 2 to 4 nt mediated efficient degradation of target RNA (duplexes 1, 3, 4, 6,
The synthetic 21 and 22 nt duplexes guided cleavage of sense as well as antisense targets within the region covered by the short duplex. This is an important result considering that a 39 bp dsRNA which forms two pairs of clusters of ˜21 nt fragments (
The target cleavage site is located 11 or 12 nt downstream of the first nucleotide that is complementary to the 21 or 22 nt guide sequence, i.e. the cleavage site is near center of the region covered by the 21 or 22 nt RNAs (
The specificity of target RNA cleavage guided by 21 and 22 nt RNAs appears exquisite as no aberrant cleavage sites are detected (
Based on the evidence that synthetic 21 and 22 nt RNAs with overhanging 3′ ends mediate. RNA interference, we propose to name the ˜21 nt RNAs “short interfering RNAs” or siRNAs and the respective RNA-protein complex a “small interfering ribonucleoprotein particle” or siRNP
1.2.5 3′ Overhangs of 20 nt on Short dsRNAs Inhibit RNAi
We have shown that short blunt-ended dsRNAs appear to be processed from the ends of the dsRNA. During our study of the length dependence of dsRNA in RNAi, we have also analyzed dsRNAs with 17 to 20 nt overhanging 3′ ends and found to our surprise that they were less potent than blunt-ended dsRNAs. The inhibitory effect of long 3′ ends was particularly pronounced for dsRNAs up to 100 bp but was less dramatic for longer dsRNAs. The effect was not due to imperfect dsRNA formation based on native gel analysis (data not shown). We tested if the inhibitory effect of long overhanging 3′ ends could be used as a tool to direct dsRNA processing to only one of the two ends of a short RNA duplex.
We synthesized four combinations of the 52 bp model dsRNA, blunt-ended, 3′ extension on only the sense strand, 3′ extension on only the antisense strand, and double 3′ extension on both strands, and mapped the target RNA cleavage sites after incubation in lysate (
The less pronounced inhibitory effect of long 3′ extensions in the case of longer dsRNAs (≧500 bp, data not shown) suggests to us that long dsRNAs may also contain internal dsRNA-processing signals or may get processed cooperatively due to the association of multiple cleavage factors.
1.2.6 A Model for dsRNA-Directed mRNA Cleavage
The new biochemical data update the model for how dsRNA targets mRNA for destruction (
Little is known about the biochemistry of RNase III homologs from plants, animals or human. Two families of RNase III enzymes have been identified predominantly by database-guided sequence analysis or cloning of cDNAs. The first RNase III family is represented by the 1327 amino acid long D. melanogaster protein drosha (Acc. AF116572). The C-terminus is composed of two RNase III and one dsRNA-binding domain and the N-terminus is of unknown function. Close homologs are also found in C. elegans (Acc. AF160248) and human (Acc. AF189011.) (Filippov et al., 2000; Wu et al., 2000). The drosha-like human RNase III was recently cloned and characterized (Wu et al., 2000). The gene is ubiquitously expressed in human tissues and cell lines, and the protein is localized in the nucleus and the nucleolus of the cell. Based-on results inferred from antisense inhibition studies, a role of this protein for rRNA processing was suggested. The second class is represented by the C. elegans gene K12H4.8 (Acc. S44849) coding for a 1822 amino acid long protein. This protein has an N-terminal RNA helicase motif which is followed by 2 RNase III catalytic domains and a dsRNA-binding motif, similar to the drosha RNase III family. There are close homologs in S. pombe (Acc. Q09884), A. thaliana (Acc. AF187317), D. melanogaster (Acc. AE003740), and human (Acc. AB028449) (Filippov et al., 2000; Jacobsen et al., 1999; Matsuda et al., 2000). Possibly the K12H4.8 RNase III/helicase is the likely candidate to be involved in RNAi.
Genetic screens in C. elegans identified rde-1 and rde-4 as essential for activation of RNAi without an effect on transposon mobilization or co-suppression (Dernburg et al., 2000; Grishok et al., 2000; Ketting and Plasterk, 2000; Tabara et al., 1999). This led to the hypothesis that these genes are important for dsRNA processing but are not involved in mRNA target degradation. The function of both genes is as yet unknown, the rde-1 gene product is a member of a family of proteins similar to the rabbit protein elF2C (Tabara et al., 1999), and the sequence of rde-4 has not yet been described. Future biochemical characterization of these proteins should reveal their molecular function.
Processing to the siRNA duplexes appears to start from the ends of both blunt-ended dsRNAs or dsRNAs with short (1–5 nt) 3′ overhangs, and proceeds in approximately 21–23 nt steps. Long (˜20 nt) 3′ staggered ends on short dsRNAs suppress RNAi, possibly through interaction with single-stranded RNA-binding proteins. The suppression of RNAi by single-stranded regions flanking short dsRNA and the lack of siRNA formation from short 30 bp dsRNAs may explain why structured regions frequently encountered in mRNAs do not lead to activation of RNAi.
Without wishing to be bound by theory, we presume that the dsRNA-processing proteins or a subset of these remain associated with the siRNA duplex after the processing reaction. The orientation of the siRNA duplex relative to these proteins determines which of the two complementary strands functions in guiding, target RNA degradation. Chemically synthesized siRNA duplexes guide cleavage of sense as well as antisense target RNA as they are able to associate with the protein components in either of the two possible orientation.
The remarkable finding that synthetic 21 and 22 nt siRNA duplexes can be used for efficient mRNA degradation provides new tools for sequence-specific regulation of gene expression in functional genomics as well as biomedical studies. The siRNAs may be effective in mammalian systems where long dsRNAs cannot be used due to the activation of the PKR response (Clemens, 1997). As such, the siRNA duplexes represent a new alternative to antisense or ribozyme therapeutics.
RNA Interference in Human Tissue Cultures
2.1 Methods
2.1.1 RNA Preparation
21 nt RNAs were chemically synthesized using Expedite RNA phosphoramidites and thymidine phosphoramidite (Proligo, Germany). Synthetic oligonucleotides were deprotected and gel-purified (Example 1), followed by Sep-Pak C18 cartridge (Waters, Milford, Mass., USA) purification (Tuschl, 1993). The siRNA sequences targeting GL2 (Acc. X65324) and GL3 luciferase (Acc. U47296) corresponded to the coding regions 153–173 relative to the first nucleotide of the start codon, siRNAs targeting RL (Acc. AF025846) corresponded to region 119–129 after the start codon. Longer RNAs were transcribed with T7 RNA polymerase from PCR products, followed by gel and Sep-Pak purification. The 49 and 484 bp GL2 or GL3 dsRNAs corresponded to position 113–161 and 113–596, respectively, relative to the start of translation; the 50 and 501 bp RL dsRNAs corresponded to position 118–167 and 118–618, respectively. PCR templates for dsRNA synthesis targeting humanized GFP (hG) were amplified from pAD3 (Kehlenbach, 1998), whereby 50 and 501 bp hG dsRNA corresponded to position 118–167 and 118–618, respectively, to the start codon.
For annealing of siRNAs, 20 μM single strands were incubated in annealing buffer (100 mM potassium acetate, 30 mM HEPES-KOH at pH 7.4, 2 mM magnesium acetate) for 1 min at 90° C. followed by 1 h at 37° C. The 37° C. incubation step was extended overnight for the 50 and 500 bp dsRNAs and these annealing reactions were performed at 8.4 μM and 0.84 μM strand concentrations, respectively.
2.1.2 Cell Culture
S2 cells were propagated in Schneider's Drosophila medium (Life Technologies) supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin at 25° C. 293, NIH/3T3, HeLa S3, COS-7 cells were grown at 37° C. in Dulbecco's modified Eagle's medium supplemented with 10% FBS, 100 units/ml penicillin and 100 μg/ml streptomycin. Cells were regularly passaged to maintain exponential growth. 24 h before transfection at approx. 80% confluency, mammalian cells were trypsinized and diluted 1:5 with fresh medium without antibiotics (1–3×105 cells/ml) and transferred to 24-well plates (500 μl/well). S2 cells were not trypsinized before split-ting. Transfection was carried out with Lipofectamine 2000 reagent (Life Technologies) as described by the manufacturer for adherent cell lines. Per well, 1.0 μg pGL2-Control (Promega) or pGL3-Control (Promega), 0.1 μg pRL-TK (Promega) and 0.28 μg siRNA duplex or dsRNA, formulated into liposomes, were applied; the final volume was 600 μl per well. Cells were incubated 20 h after transfection and appeared healthy thereafter. Luciferase expression was subsequently monitored with the Dual luciferase assay (Promega). Transfection efficiencies were determined by fluorescence microscopy for mammalian cell lines after co-transfection of 1.1 μg hGFP-encoding pAD3 and 0.28 μg invGL2 in GL2 siRNA and were 70–90%. Reporter plasmids were amplified in XL-1 Blue (Stratagene) and purified using the Qiagen EndoFree Maxi Plasmid Kit.
2.2 Results and Discussion
To test whether siRNAs are also capable of mediating RNAi in tissue culture, we synthesized 21 nt siRNA duplexes with symmetric 2 nt 3′ overhangs directed against reporter genes coding for sea pansy (Renilla reniformis) and two sequence variants of firefly (Photinus pyralis, GL2 and GL3) luciferases (
The 2 nt 3′ overhang in all siRNA duplexes, except for uGL2, was composed of (2′-deoxy) thymidine. Substituion of uridine by thymidine in the 3′ overhang was well tolerated in the D. melanogaster in vitro sytem and the sequence of the overhang was uncritical for target recognition. The thymidine overhang was chosen, because it is supposed to enhance nuclease resistance of siRNAs in the tissue culture medium and within transfected cells. Indeed, the thymidine-modified GL2 siRNA was slightly more potent than the unmodified uGL2 siRNA in all cell lines tested (
In co-transfection experiments, 25 nM siRNA duplexes with respect to the final volume of tissue culture medium were used (
In order to monitor the effect of longer dsRNAs on mammalian cells, 50 and 500 bp dsRNAs cognate to the reporter genes were prepared. As nonspecific control, dsRNAs from humanized GFP (hG) (Kehlenbach, 1998) was used. When dsRNAs were co-transfected, in identical amounts (not concentrations) to the siRNA duplexes, the reporter gene expression was strongly and unspecifically reduced. This effect is illustrated for HeLa cells as a representative example (
Surprisingly, despite the strong unspecific decrease in reporter gene expression, we reproducibly detected additional sequence-specific, dsRNA-mediated silencing. The specific silencing effects, however, were only apparent when the relative reporter gene activities were normalized to the hG dsRNA controls (
In summary, we have demonstrated for the first time siRNA-mediated gene silencing in mammalian cells. The use of short siRNAs holds great promise for inactivation of gene function in human tissue culture and the development of gene-specific therapeutics.
Specific Inhibition of Gene Expression by RNA Interference
3.1 Materials and Methods
3.1.1 RNA Preparation and RNAi Assay
Chemical RNA synthesis, annealing, and luciferase-based RNAi assays were performed as described in Examples 1 or 2 or in previous publications (Tuschl et al., 1999; Zamore et al., 2000). All siRNA duplexes were directed against firefly luciferase, and the luciferase mRNA sequence was derived from pGEM-luc (GenBank acc. X65316) as described (Tuschl et al., 1999). The siRNA duplexes were incubated in D. melanogaster RNAi/translation reaction for 15 min prior to addition of mRNAs. Translation-based RNAi assays were performed at least in triplicates.
For mapping of sense target RNA cleavage, a 177-nt transcript was generated, corresponding to the firefly luciferase sequence between positions 113–273 relative to the start codon, followed by the 17-nt complement of the SP6 promoter sequence. For mapping of antisense target RNA cleavage, a 166-nt transcript was produced from a template, which was amplified from plasmid sequence by PCR using 5′ primer TAATACGACTCACTATAGAGCCCATATCGTTTCATA (T7 promoter in bold) [SEQ ID NO: 5] and 3′ primer AGAGGATGGAACCGCTGG [SEQ ID NO: 6]. The target sequence corresponds to the complement of the firefly luciferase sequence between positions 50–215 relative to the start codon. Guanylyl transferase labelling was performed as previously described (Zamore et al., 2000). For mapping of target RNA cleavage, 100 nM siRNA duplex was incubated with 5 to 10 nM target RNA in D. melanogaster embryo lysate under standard conditions (Zamore et al., 2000) for 2 h at 25EC. The reaction was stopped by the addition of 8 volumes of proteinase K buffer (200 mM Tris-HCl pH 7.5, 25 mM EDTA, 300 mM NaCl, 2% w/v sodium dodecyl sulfate). Proteinase K (E. M. Merck, dissolved in water) was added to a final concentration of 0.6 mg/ml. The reactions were then incubated for 15 mm at 65EC, extracted with phenol/chloroform/isoamyl alcohol (25:24:1) and precipitated with 3 volumes of ethanol. Samples were located on 6% sequencing gels. Length standards were generated by partial RNase T1 digestion and partial base hydrolysis of the cap-labelled sense or antisense target RNAs.
3.2 Results
3.2.1 Variation of the 3′ Overhang in Duplexes of 21-nt siRNAs
As described above, 2 or 3 unpaired nucleotides at the 3′ end of siRNA duplexes were more efficient in target RNA degradation than the respective blunt-ended duplexes. To perform a more comprehensive analysis of the function of the terminal nucleotides, we synthesized five 21-nt sense siRNAs, each displayed by one nucleotide relative to the target RNA, and eight 21-nt antisense siRNAs, each displaced by one nucleotide relative to the target (
The ability of 21-nt siRNA duplexes to mediate RNAi is dependent on the number of overhanging nucleotides or base pairs formed. Duplexes with four to six 3′ overhanging nucleotides were unable to mediate RNAi (
3.2.2 Length Variation of the Sense siRNA Paired to an Invariant 21-nt Antisense siRNA
In order to investigate the effect of length of siRNA on RNAi, we prepared 3 series of siRNA duplexes, combining three 21-nt antisense strands with eight, 18- to 25-nt sense strands. The 3′ overhang of the antisense siRNA was fixed to 1, 2, or 3 nt in each siRNA duplex series, while the sense siRNA was varied at its 3′ end (
3.2.3 Length Variation of siRNA Duplexes with a Constant 2-nt 3′ Overhang
We then examined the effect of simultaneously changing the length of both siRNA strands by maintaining symmetric 2-nt 3′ overhangs (
3.2.4 2′-Deoxy and 2′-O-Methyl-Modified siRNA Duplexes
To assess the importance of the siRNA ribose residues for RNAi, duplexes with 21-nt siRNAs and 2-nt 3′ overhangs with 2′-deoxy- or 2′-O-methyl-modified strands were examined (
3.2.5 Definition of Target RNA Cleavage Sites
Target RNA cleavage positions were previously determined for 22-nt siRNA duplexes and for a 21-nt/22-nt duplex. It was found that the position of the target RNA cleavage was located in the centre of the region covered by the siRNA duplex, 11 or 12 nt downstream of the first nucleotide that was complementary to the 21- or 22-nt siRNA guide sequence. Five distinct 21-nt siRNA duplexes with 2-nt 3′ overhang (
The cleavage sites for both, sense and antisense target RNAs were located in the middle of the region spanned by the siRNA duplexes. The cleavage sites for each target produced by the 5 different duplexes varied by 1-nt according to the 1-nt displacement of the duplexes along the target sequences. The targets were cleaved precisely 11 nt downstream of the target position complementary to the 3′-most nucleotide of the sequence-complementary guide siRNA (
In order to determine, whether the 5′ or the 3′ end of the guide siRNA sets the ruler for target RNA cleavage, we devised the experimental strategy outlined in
3.2.6 Sequence Effects and 2′-Deoxy Substitutions in the 3′ Overhang
A 2-nt 3′overhang is preferred for siRNA function. We wanted to know, if the sequence of the overhanging nucleotides contributes to target recognition, or if it is only a feature required for reconstitution of the endonuclease complex (RISC or siRNP). We synthesized sense and antisense siRNAs with AA, CC, GG, UU, and UG 3′ overhangs and included the 2-deoxy modifications TdG and TT. The wild-type siRNAs contained AA in the sense 3′ overhang and UG in the antisense 3′ overhang (AA/UG). All siRNA duplexes were functional in the interference assay and reduced target expression at least 5-fold (
Changes in the sequence of the 3′ overhang of the sense siRNA did not reveal any sequence-dependent effects, which was expected, because the sense siRNA must not contribute to sense target mRNA recognition.
3.2.7 Sequence Specifity of Target Recognition
In order to examine the sequence-specifity of target recognition, we introduced sequence changes into the paired segments of siRNA duplexes and determined the efficiency of silencing. Sequence changes were introduced by inverting short segments of 3- or 4-nt length or as point mutations (
3.3 Discussion
siRNAs are valuable reagents for inactivation of gene expression, not only in insect cells, but also in mammalian cells, with a great potential for therapeutic application. We have systematically analysed the structural determinants of siRNA duplexes required to promote efficient target RNA degradation in D. melanogaster embryo lysate, thus providing rules for the design of most potent siRNA duplexes. A perfect siRNA duplex is able to silence gene expression with an efficiency comparable to a 500 bp dsRNA, given that comparable quantities of total RNA are used.
3.4 The siRNA User Guide
Efficiently silencing siRNA duplexes are preferably composed of 21-nt antisense siRNAs, and should be selected to form a 19 bp double helix with 2-nt 3′ overhanging ends. 2′-deoxy substitutions of the 2-nt 3′ overhanging ribonucleotides do not affect RNAi, but help to reduce the costs of RNA synthesis and may enhance RNAse resistance of siRNA duplexes. More extensive 2′-deoxy or 2′-O-methyl modifications, however, reduce the ability of siRNAs to mediate RNAi, probably by interfering with protein association for siRNAP assembly.
Target recognition is a highly sequence-specific process, mediated by the siRNA complementary to the target. The 3′-most nucleotide of the guide siRNA does not contribute to specificity of target recognition, while the penultimate nucleotide of the 3′ overhang affects target RNA cleavage, and a mismatch reduces RNAi 2- to 4-fold. The 5′ end of a guide siRNA also appears more permissive for mismatched target RNA recognition when compared to the 3′ end. Nucleotides in the centre of the siRNA, located opposite the target RNA cleavage site, are important specificity determinants and even single nucleotide changes reduce RNAi to undetectable level. This suggests that siRNA duplexes may be able to discriminate mutant or polymorphic alleles in gene targeting experiments, which may become an important feature for future therapeutic developments.
Sense and antisense siRNAs, when associated with the protein components of the endonclease complex or its commitment complex, were suggested to play distinct roles; the relative orientation of the siRNA duplex in this complex defines which strand can be used for target recognition. Synthetic siRNA duplexes have dyad symmetry with respect to the double-helical structure, but not with respect to sequence. The association of siRNA duplexes with the RNAi proteins in the D. melanogaster lysate will lead to formation of two asymmetric complexes. In such hypothetical complexes, the chiral environment is distinct for sense and antisense siRNA, hence their function. The prediction obviously does not apply to palindromic siRNA sequences, or to RNAi proteins that could associate as homodimers. To minimize sequence effects, which may affect the ratio of sense and antisense-targeting siRNPs, we suggest to use siRNA sequences with identical 3′ overhanging sequences. We recommend to adjust the sequence of the overhang of the sense siRNA to that of the antisense 3′ overhang, because the sense siRNA does not have a target in typical knock-down experiments. Asymmetry in reconstitution of sense and anti-sense-cleaving siRNPs could be (partially) responsible for the variation in RNAi efficiency observed for various 21-nt siRNA duplexes with 2-nt 3′ overhangs used in this study (
Tuschl, Thomas, Elbashir, Sayda Mahgoub, Lendeckel, Winfried
Patent | Priority | Assignee | Title |
10000754, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
10004814, | Nov 11 2013 | MERCK SHARP & DOHME CORP, | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
10036025, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
10041073, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAi compounds |
10047388, | May 28 2004 | Asuragen, Inc. | Methods and compositions involving MicroRNA |
10086063, | Sep 23 2015 | Regents of the University of Minnesota | Methods of making and using live attenuated viruses |
10106793, | Feb 01 2002 | Life Technologies Corporation | Double-stranded oligonucleotides |
10131904, | Feb 11 2008 | PHIO PHARMACEUTICALS CORP | Modified RNAi polynucleotides and uses thereof |
10138485, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Neutral nanotransporters |
10138497, | Apr 15 2011 | MOLECULAR TRANSFER, INC. | Agents for improved delivery of nucleic acids to eukaryotic cells |
10167471, | Jan 05 2009 | PHIO PHARMACEUTICALS CORP | Inhibition of PCSK9 through RNAI |
10184124, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | RNA interference in ocular indications |
10196640, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
10202615, | Dec 10 2010 | Vanderbilt University | Mammalian genes involved in toxicity and infection |
10227588, | Oct 04 2013 | Novartis AG | 3′end caps for RNAi agents for use in RNA interference |
10233451, | May 03 2002 | Duke University | Method of regulating gene expression |
10240149, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAi compounds |
10266829, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
10323246, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
10329564, | Sep 19 2007 | Applied Biosystems, LLC | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof |
10329568, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
10351852, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
10358497, | Sep 29 2015 | Amgen Inc. | Methods of treating cardiovascular disease with an ASGR inhibitor |
10370663, | Nov 13 2012 | LONZA SALES AG | Delivery of therapeutic agent |
10378012, | Jul 29 2014 | MONSANTO TECHNOLOGY LLC | Compositions and methods for controlling insect pests |
10383935, | Sep 23 2015 | Regents of the University of Minnesota | Methods of making and using live attenuated viruses |
10392619, | Oct 12 2009 | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro | |
10421964, | Jul 23 2015 | Arcturus Therapeutics, Inc. | UNA oligomers and compositions for treating amyloidosis |
10450565, | Jan 10 2017 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use |
10457945, | May 22 2007 | Arcturus Therapeutics, Inc. | UNA oligomers for therapeutics with prolonged stability |
10472625, | Mar 30 2000 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA sequence-specific mediators of RNA interference |
10479992, | Feb 04 2009 | PHIO PHARMACEUTICALS CORP | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
10487149, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | Nucleic acid-polypeptide compositions and uses thereof |
10494631, | Nov 26 2009 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
10519446, | Oct 04 2013 | Novartis AG | Organic compounds to treat hepatitis B virus |
10519447, | Apr 01 2015 | ARCTURUS THERAPEUTICS, INC | Therapeutic UNA oligomers and uses thereof |
10532104, | Aug 31 2012 | The General Hospital Corporation | Biotin complexes for treatment and diagnosis of Alzheimer'S disease |
10538762, | Oct 14 2014 | The Board of Regents of the University of Texas System | Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAS targeting the expanded hexanucleotide repeat |
10550188, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | Nucleic acid-polypeptide compositions and uses thereof |
10570414, | Feb 20 2007 | MONSANTO TECHNOLOGY LLC | Invertebrate microRNAs |
10583151, | Dec 30 2010 | Cedars-Sinai Medical Center | Polymalic acid-based nanobiopolymer compositions |
10584335, | Aug 24 2010 | SIRNA THERAPEUTICS, INC. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
10597676, | Jul 19 2013 | MONSANTO TECHNOLOGY LLC | Compositions and methods for controlling Leptinotarsa |
10604574, | Jun 30 2016 | ONCORUS, INC | Oncolytic viral delivery of therapeutic polypeptides |
10604758, | Mar 25 2014 | Arcturus Therapeutics, Inc. | Therapeutic oligomers for treating amyloidosis |
10626398, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
10633654, | Feb 11 2008 | PHIO PHARMACEUTICALS CORP | Modified RNAi polynucleotides and uses thereof |
10633656, | Dec 01 2000 | Max-Planck-Gesellschaft zur Forderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA interference mediating small RNA molecules |
10655184, | Sep 13 2011 | INTERPACE DIAGNOSTICS, LLC | Methods and compositions involving miR-135b for distinguishing pancreatic cancer from benign pancreatic disease |
10662428, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
10662430, | Mar 24 2010 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
10683500, | Mar 25 2014 | ARCTURUS THERAPEUTICS, INC | UNA oligomers having reduced off-target effects in gene silencing |
10711106, | Jul 25 2013 | The University of Chicago | High aspect ratio nanofibril materials |
10729787, | Nov 11 2013 | SIRNA THERAPEUTICS, INC. | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
10731155, | Jul 12 2001 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
10731157, | Aug 24 2015 | HALO-BIO RNAI THERAPEUTICS, INC | Polynucleotide nanoparticles for the modulation of gene expression and uses thereof |
10736848, | Oct 12 2007 | IMMUNE DISEASE INSTITUTE, INC | Vaccine nanotechnology |
10774330, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAI compounds |
10774332, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
10787519, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | Nucleic acid-polypeptide compositions and uses thereof |
10792299, | Dec 26 2014 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with kras mutation |
10800848, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | Nucleic acid-polypeptide compositions and uses thereof |
10801028, | Oct 14 2009 | GREENLIGHT BIOSCIENCES, INC | Compositions for controlling Varroa mites in bees |
10808247, | Jul 06 2015 | PHIO PHARMACEUTICALS CORP | Methods for treating neurological disorders using a synergistic small molecule and nucleic acids therapeutic approach |
10815485, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | RNA interference in skin indications |
10844385, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | Beta-catenin nucleic acids and uses thereof |
10858656, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | KRAS nucleic acids and uses thereof |
10876119, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAI compounds |
10876121, | Apr 01 2016 | AVIDITY BIOSCIENCES LLC; AVIDITY BIOSCIENCES, INC | EGFR nucleic acids and uses thereof |
10881743, | Dec 06 2017 | AVIDITY BIOSCIENCES LLC | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
10883118, | Apr 15 2011 | Molecular Transfer Inc. | Agents for improved delivery of nucleic acids to eukaryotic cells |
10888579, | Nov 07 2007 | GREENLIGHT BIOSCIENCES, INC | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
10889815, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
10900038, | Sep 19 2007 | Applied Biosystems, LLC | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof |
10900039, | Sep 05 2014 | PHIO PHARMACEUTICALS CORP | Methods for treating aging and skin disorders using nucleic acids targeting Tyr or MMP1 |
10913948, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | RNA interference in dermal and fibrotic indications |
10920226, | Nov 14 2002 | Thermo Fisher Scientific Inc. | siRNA targeting LDHA |
10933081, | Sep 21 2016 | Alnylam Pharmaceuticals, Inc | Myostatin iRNA compositions and methods of use thereof |
10934547, | Feb 20 2017 | Northwestern University | Use of trinucleotide repeat RNAs to treat cancer |
10934550, | Dec 02 2013 | PHIO PHARMACEUTICALS CORP | Immunotherapy of cancer |
10959952, | Jun 10 2015 | Board of Regents, The University of Texas System | Use of exosomes for the treatment of disease |
10968449, | Jan 22 2015 | MONSANTO TECHNOLOGY LLC | Compositions and methods for controlling Leptinotarsa |
11001845, | Jul 06 2015 | PHIO PHARMACEUTICALS CORP | Nucleic acid molecules targeting superoxide dismutase 1 (SOD1) |
11008570, | Oct 04 2013 | Novartis AG | 3′ end caps for RNAi agents for use in RNA interference |
11017851, | Nov 26 2019 | Cypress Semiconductor Corporation | Silicon-oxide-nitride-oxide-silicon based multi level non-volatile memory device and methods of operation thereof |
11021707, | Oct 19 2015 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering nucleic acid compounds targeting long non-coding RNA |
11066472, | Sep 29 2015 | Amgen Inc. | Methods of treating cardiovascular disease with an anti-ASGR antibody or binding fragments thereof |
11078280, | Jun 30 2016 | ONCORUS, INC | Oncolytic viral delivery of therapeutic polypeptides |
11091770, | Apr 01 2014 | MONSANTO TECHNOLOGY LLC | Compositions and methods for controlling insect pests |
11118178, | Mar 24 2010 | Phio Pharmaceuticals Corp. | Reduced size self-delivering RNAI compounds |
11124792, | Jul 29 2014 | MONSANTO TECHNOLOGY LLC | Compositions and methods for controlling insect pests |
11193126, | Oct 29 2010 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
11198870, | Nov 14 2002 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
11203756, | Jan 10 2017 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use |
11246941, | Dec 06 2017 | AVIDITY BIOSCIENCES, INC. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11253607, | Dec 06 2017 | AVIDITY BIOSCIENCES LLC | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11254940, | Nov 19 2008 | PHIO PHARMACEUTICALS CORP | Inhibition of MAP4K4 through RNAi |
11279934, | Apr 28 2014 | PHIO PHARMACEUTICALS CORP | Methods for treating cancer using nucleic acids targeting MDM2 or MYCN |
11352628, | Dec 26 2014 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with KRAS mutation |
11355185, | Nov 26 2019 | Cypress Semiconductor Corporation | Silicon-oxide-nitride-oxide-silicon multi-level non-volatile memory device and methods of fabrication thereof |
11359201, | Oct 12 2009 | Methods and compositions for modulating gene expression using oligonucleotide based drugs administered in vivo or in vitro | |
11377667, | Jul 19 2013 | MONSANTO TECHNOLOGY LLC | Compositions and methods for controlling Leptinotarsa |
11396654, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Neutral nanotransporters |
11446387, | Mar 27 2020 | AVIDITY BIOSCIENCES, INC | Compositions and methods of treating muscle dystrophy |
11497814, | Dec 06 2017 | AVIDITY BIOSCIENCES, INC. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11525137, | Mar 19 2020 | AVIDITY BIOSCIENCES, INC | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
11529428, | Nov 11 2013 | Merck Sharp & Dohme Corp | Systemic delivery of myostatin short interfering nucleic acids (siNA) conjugated to a lipophilic moiety |
11547667, | Oct 12 2007 | Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc.; President and Fellows of Harvard College; The Children's Medical Center Corporation | Vaccine nanotechnology |
11554176, | Dec 06 2017 | AVIDITY BIOSCIENCES, INC. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11555190, | Mar 19 2020 | AVIDITY BIOSCIENCES, INC | Compositions and methods of treating Facioscapulohumeral muscular dystrophy |
11576980, | Dec 06 2017 | AVIDITY BIOSCIENCES, INC. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11578328, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
11583591, | Dec 06 2017 | AVIDITY BIOSCIENCES LLC | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11584933, | Mar 24 2010 | Phio Pharmaceuticals Corp. | RNA interference in ocular indications |
11638760, | Nov 27 2017 | MERSANA THERAPEUTICS, INC | Pyrrolobenzodiazepine antibody conjugates |
11667915, | Feb 04 2009 | Phio Pharmaceuticals Corp. | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
11712478, | Dec 06 2017 | AVIDITY BIOSCIENCES, INC. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11795457, | Dec 09 2014 | The Board of Regents of the University of Texas System | Compositions and methods for treatment of Friedreich's Ataxia |
11840690, | Oct 14 2014 | The Board of Regents of the University of Texas System | Allele selective inhibition of mutant C9orf72 foci expression by duplex RNAs targeting the expanded hexanucleotide repeat |
11865081, | Dec 29 2017 | Virogin Biotech Canada Ltd | Oncolytic viral delivery of therapeutic polypeptides |
11872287, | Dec 06 2017 | AVIDITY BIOSCIENCES, INC. | Compositions and methods of treating muscle atrophy and myotonic dystrophy |
11884920, | Jan 10 2017 | Arrowhead Pharmaceuticals, Inc. | Alpha-1 antitrypsin (AAT) RNAi agents, compositions including AAT RNAi agents, and methods of use |
7427605, | Mar 31 2005 | CALANDO PHARMACEUTICALS, INC | Inhibitors of ribonucleotide reductase subunit 2 and uses thereof |
7452987, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
7713943, | Aug 14 2002 | Silence Therapeutics GMBH | Further use of protein kinase N beta |
7749977, | Nov 12 1997 | QUARK PHARMACUTICALS, INC | Therapeutic modulation of the Fas pathway |
7767652, | Jul 21 2004 | Medtronic, Inc. | Medical devices and methods for reducing localized fibrosis |
7795419, | May 26 2004 | Rosetta Genomics Ltd | Viral and viral associated miRNAs and uses thereof |
7888010, | May 28 2004 | Applied Biosystems, LLC | Methods and compositions involving microRNA |
7893036, | Jul 12 2001 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
7893245, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
7919245, | May 28 2004 | ASURAGEN, INC | Methods and compositions involving microRNA |
7960359, | Nov 12 2004 | ASURAGEN, INC | Methods and compositions involving miRNA and miRNA inhibitor molecules |
7964196, | May 25 2004 | BIOMED REALTY, L P | Self-assembling nanoparticle drug delivery system |
8003320, | May 28 2004 | ASURAGEN, INC | Methods and compositions involving MicroRNA |
8058250, | Nov 12 2004 | ASURAGEN, INC | Methods and compositions involving miRNA and miRNA inhibitor molecules |
8058255, | Dec 23 2004 | Applied Biosystems, LLC | Methods and compositions concerning siRNA's as mediators of RNA interference |
8067011, | Apr 07 2006 | BIOMED REALTY, L P | Compositions and methods for treating B-cell malignancies |
8067570, | Jan 20 2006 | QUARK PHARMACUTICALS, INC | Therapeutic uses of inhibitors of RTP801 |
8071562, | Dec 01 2007 | MIRNA THERAPEUTICS, INC | MiR-124 regulated genes and pathways as targets for therapeutic intervention |
8076307, | Oct 27 2005 | NATIONAL UNIVERSITY CORPORATION NARA INSTITUTE OF SCIENCE AND TECHNOLOGY; Kazusa DNA Research Institute | Formation/elongation of axon by inhibiting the expression or function of Singar and application to nerve regeneration |
8084600, | May 04 2006 | Novartis AG | Short interfering ribonucleic acid (siRNA) with improved pharmacological properties |
8088359, | Jun 04 2004 | University of Geneva | Means and methods of using a NADPH oxidase inhibitor for the treatment of hearing loss and phantom hearing |
8097712, | Nov 07 2007 | GREENLIGHT BIOSCIENCES, INC | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
8097716, | Aug 28 2003 | Novartis AG | Interfering RNA duplex having blunt-ends and 3′-modifications |
8137910, | May 03 2002 | Duke University | Method of regulating gene expression |
8148342, | Sep 28 2004 | Quark Pharmaceuticals Inc. | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
8153110, | Nov 22 2006 | TILE UNIVERSITY OF TOKYO; The University of Tokyo | Environment-responding siRNA carrier using disulfide-cross-linked polymeric micelle |
8173611, | Nov 12 2004 | Applied Biosystems, LLC | Methods and compositions involving miRNA and miRNA inhibitor molecules |
8173616, | May 02 2008 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | RNA-induced translational silencing and cellular apoptosis |
8193334, | Apr 04 2007 | Massachusetts Institute of Technology | Polymer-encapsulated reverse micelles |
8202845, | Apr 18 2002 | PHIO PHARMACEUTICALS CORP | Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification |
8227441, | Mar 01 2002 | Celltech R & D, Inc. | Methods to increase or decrease bone density |
8232256, | Jul 21 2006 | Silence Therapeutics GMBH | Means for inhibiting the expression of protein kinase 3 |
8232260, | Jul 12 2001 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
8236944, | Sep 05 2002 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
8242257, | Sep 05 2002 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
8258111, | May 08 2008 | MIRNA THERAPEUTICS, INC | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
8277812, | Oct 12 2008 | President and Fellows of Harvard College | Immunonanotherapeutics that provide IgG humoral response without T-cell antigen |
8278287, | Apr 15 2008 | QUARK PHARMACEUTICALS, INC | siRNA compounds for inhibiting NRF2 |
8293253, | Oct 28 2004 | IDEXX LABORATORIES INC | Compositions for controlled delivery of pharmaceutically active compounds |
8299044, | May 19 2003 | Genecare Research Institute Co., Ltd. | Apoptosis inducer for cancer cell |
8309614, | Apr 11 2008 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant leu-leu-leu tripeptide for effective cytoplasmic drug delivery |
8323698, | May 15 2006 | Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc. | Polymers for functional particles |
8324370, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
8329463, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8329888, | Mar 23 2006 | ROCHE INNOVATION CENTER COPENHAGEN A S | Small internally segmented interfering RNA |
8343497, | Oct 12 2008 | President and Fellows of Harvard College | Targeting of antigen presenting cells with immunonanotherapeutics |
8343498, | Oct 12 2008 | President and Fellows of Harvard College | Adjuvant incorporation in immunonanotherapeutics |
8344128, | May 04 2006 | Novartis AG | Short interfering ribonucleic acid (siRNA) for oral administration |
8361510, | Jun 16 2008 | Georgia Tech Research Corporation | Nanogels for cellular delivery of therapeutics |
8361714, | Sep 14 2007 | ASURAGEN, INC | Micrornas differentially expressed in cervical cancer and uses thereof |
8361988, | Jan 17 2007 | LCB PHARMA INC | Nucleoside and nucleotide analogues with quaternary carbon centers and methods of use |
8362229, | Feb 08 2006 | QUARK PHARMACUTICALS, INC | Tandem siRNAS |
8362231, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8367113, | May 15 2006 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Polymers for functional particles |
8372968, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8394628, | Mar 30 2000 | University of Massachusetts; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
8404654, | Jan 20 2006 | Quark Pharmaceuticals, Inc. | Treatment or prevention of oto-pathologies by inhibition of pro-apoptotic genes |
8404831, | May 04 2006 | Novartis AG | Short interfering ribonucleic acid (siRNA) for oral administration |
8404832, | May 04 2006 | Novartis AG | Short interfering ribonucleic acid (siRNA) for oral administration |
8409796, | May 03 2002 | Duke University | Method of regulating gene expression |
8410069, | Mar 22 2007 | Quark Pharmaceuticals, Inc. | Oligoribonucleotide inhibitors of Nrf2 and methods of use thereof for treatment of cancer |
8410260, | Sep 21 2005 | L'Oreal | Double-stranded RNA oligonucleotides which inhibit tyrosinase expression |
8410334, | Feb 20 2007 | MONSANTO TECHNOLOGY LLC | Invertebrate microRNAs |
8420391, | Mar 30 2000 | University of Massachusetts; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
8431692, | Jun 06 2008 | QUARK PHARMACEUTICALS, INC | Compositions and methods for treatment of ear disorders |
8445237, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8445667, | Nov 14 2002 | Thermo Fisher Scientific Inc | SiRNA targeting cyclin-dependent kinase inhibitor 1B (p27, Kip1) (CDKN1B) |
8461125, | Feb 14 2008 | THE CHILDREN S HOSPITAL OF PHILADELPHIA | Compositions and methods to treat asthma |
8465914, | May 28 2004 | Asuragen, Inc. | Method and compositions involving microRNA |
8470792, | Dec 04 2008 | PHIO PHARMACEUTICALS CORP | Compositions and methods for selective inhibition of VEGF |
8507457, | Nov 07 2007 | GREENLIGHT BIOSCIENCES, INC | Compositions for conferring tolerance to viral disease in social insects, and the use thereof |
8524680, | Feb 01 2002 | Applied Biosystems, LLC | High potency siRNAS for reducing the expression of target genes |
8524681, | Sep 19 2007 | Applied Biosystems, LLC | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof |
8530438, | Jul 12 2001 | University of Massachusetts | Vivo production of small interfering RNAs that mediate gene silencing |
8541384, | Jul 24 2002 | The Trustees of the University of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
8546345, | Jul 24 2002 | The Trustees of the University of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
8552171, | Mar 30 2000 | University of Massachusetts; Whitehead Insititute for Biomedical Research; Massachusetts Institute of Technology; Max-Planck-Gesellschaft zur Föderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
8557785, | Jul 12 2001 | University of Massachusetts | In vivo production of small interfering RNAS that mediate gene silencing |
8562998, | Oct 12 2008 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Targeting of antigen presenting cells with immunonanotherapeutics |
8568971, | May 28 2004 | Asuragen, Inc. | Methods and compositions involving microRNA |
8591905, | Oct 12 2008 | President and Fellows of Harvard College | Nicotine immunonanotherapeutics |
8614309, | Oct 03 2007 | QUARK PHARMACEUTICALS, INC | Double-stranded RNA directed to CASP2 and methods of use thereof |
8614311, | Dec 12 2007 | QUARK PHARMACEUTICALS, INC | RTP801L siRNA compounds and methods of use thereof |
8632997, | Mar 30 2000 | University of Massachusetts; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
8637028, | Oct 12 2008 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Adjuvant incorporation in immunonanotherapeutics |
8637477, | Aug 30 2007 | KAIMI BIOMEDICINE CHENGDU CO , LTD | Antigenic compositions and use of same in the targeted delivery of nucleic acids |
8653252, | Mar 21 2003 | ROCHE INNOVATION CENTER COPENHAGEN A S | Short interfering RNA (siRNA) analogues |
8664189, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | RNA interference in skin indications |
8673873, | Dec 28 2005 | Arrowhead Research Corporation | RNAi-mediated inhibition of phosphodiesterase type 4 for treatment of cAMP-related ocular disorders |
8703930, | Apr 09 2004 | Genecare Research Institute Co., Ltd. | Cancer cell-specific apoptosis-inducing agents that target chromosome stabilization-associated genes |
8709483, | Mar 31 2006 | Massachusetts Institute of Technology | System for targeted delivery of therapeutic agents |
8722639, | Jun 04 2004 | University of Geneva | Means and methods for the treatment of hearing loss and phantom hearing |
8742092, | Mar 30 2000 | University of Massachusetts; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
8765699, | Sep 28 2004 | QUARK PHARMACUTICALS, INC | Oligoribonucleotides and methods of use thereof for treatment of alopecia, acute renal failure and other diseases |
8765709, | Nov 12 2004 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
8765930, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8778902, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8785408, | Jun 27 2007 | QUARK PHARMACEUTICALS INC | Compositions and methods for reducing or protecting against delayed graft function (DGF) |
8790922, | Mar 30 2000 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA sequence-specific mediators of RNA interference |
8795648, | Apr 11 2008 | Cedars-Sinai Medical Center | Poly(beta malic acid) with pendant Leu-Leu-Leu tripeptide for effective cytoplasmic drug delivery |
8796016, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8796235, | Feb 21 2003 | University of South Florida | Methods for attenuating dengue virus infection |
8796239, | Nov 26 2009 | QUARK PHARMACEUTICALS, INC | Sirna compounds comprising terminal substitutions |
8796443, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAi compounds |
8802153, | Mar 31 2006 | Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc. | System for targeted delivery of therapeutic agents |
8808747, | Apr 17 2007 | Baxter International Inc; BAXTER HEALTHCARE S A | Nucleic acid microparticles for pulmonary delivery |
8809296, | May 19 2003 | Genecare Research Institute Co., Ltd. | Apoptosis inducer for cancer cell |
8815818, | Jul 18 2008 | PHIO PHARMACEUTICALS CORP | Phagocytic cell delivery of RNAI |
8815821, | Feb 01 2002 | Life Technologies Corporation | Double-stranded oligonucleotides |
8822426, | May 05 2009 | GREENLIGHT BIOSCIENCES, INC | Prevention and treatment of nosema disease in bees |
8822428, | Sep 21 2005 | L'Oreal | Double-stranded RNA oligonucleotides which inhibit tyrosinase expression |
8828960, | Jul 17 2007 | IDEXX LABORATORIES, INC | Amino acid vitamin ester compositions for controlled delivery of pharmaceutically active compounds |
8853384, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8859751, | Jan 07 2010 | QUARK PHARMACEUTICALS, INC | Oligonucleotide compounds comprising non-nucleotide overhangs |
8865188, | Sep 09 2011 | BIOMED REALTY, L P | Methods and compositions for controlling assembly of viral proteins |
8895718, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8895721, | Dec 01 2000 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA interference mediating small RNA molecules |
8901097, | Nov 08 2009 | Rutgers, The State University of New Jersey | Methods for delivery of siRNA to the spinal cord and therapies arising therefrom |
8906381, | Oct 12 2008 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Immunonanotherapeutics that provide IGG humoral response without T-cell antigen |
8916693, | Sep 17 2009 | Nektar Therapeutics | Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
8921105, | May 03 2002 | Duke University | Method of regulating gene expression |
8932595, | Oct 12 2008 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Nicotine immunonanotherapeutics |
8933044, | Dec 01 2000 | Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts; MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | RNA interference mediating small RNA molecules |
8933215, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
8946177, | Nov 12 2004 | Mima Therapeutics, Inc | Methods and compositions involving miRNA and miRNA inhibitor molecules |
8946180, | Apr 18 2002 | PHIO PHARMACEUTICALS CORP | Means and methods for the specific modulation of target genes in the CNS and the eye and methods for their identification |
8946403, | Jul 24 2002 | The Trustees of the University of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
8957041, | May 04 2006 | Novartis AG | Short interfering ribonucleic acid (siRNA) for oral administration |
8957197, | Mar 30 2000 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA sequence-specific mediators of RNA interference |
8962584, | Oct 14 2009 | GREENLIGHT BIOSCIENCES, INC | Compositions for controlling Varroa mites in bees |
9012138, | Mar 30 2000 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA sequence-specific mediators of RNA interference |
9012621, | Mar 30 2000 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V.; Massachusetts Institute of Technology; Whitehead Institute for Biomedical Research; University of Massachusetts | RNA sequence-specific mediators of RNA interference |
9017695, | Apr 14 2009 | BIOMED REALTY, L P | Chimeric therapeutics, compositions, and methods for using same |
9051570, | May 22 2007 | ARCTURUS THERAPEUTICS, INC | UNA oligomers for therapeutics |
9056903, | Jan 20 2006 | Silence Therapeutics GMBH | Therapeutic uses of inhibitors of RTP801 |
9066978, | May 26 2010 | SELECTA BIOSCIENCES, INC | Dose selection of adjuvanted synthetic nanocarriers |
9074211, | Nov 19 2008 | PHIO PHARMACEUTICALS CORP | Inhibition of MAP4K4 through RNAI |
9078855, | Aug 14 2002 | Silence Therapeutics GMBH | Further use of protein kinase N beta |
9080014, | May 15 2006 | Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc. | Polymers for functional particles |
9080171, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAi compounds |
9080215, | Sep 14 2007 | Asuragen, Inc. | MicroRNAs differentially expressed in cervical cancer and uses thereof |
9089590, | Dec 04 2003 | University of South Florida | Polynucleotides for reducing respiratory syncytial virus gene expression |
9089591, | Jun 06 2008 | Quark Pharmaceuticals, Inc. | Compositions and methods for treatment of ear disorders |
9089610, | Aug 19 2008 | Nektar Therapeutics | Complexes of small-interfering nucleic acids |
9095504, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | RNA interference in ocular indications |
9109228, | Sep 13 2005 | Trustees of Dartmouth College | Compositions and methods for regulating RNA translation via CD154 CA-dinucleotide repeat |
9133462, | Jul 05 2007 | Arrowhead Research Corporation | dsRNA for treating viral infection |
9150863, | Jul 24 2002 | The Trustees of the University of Pennsylvania | Compositions and methods for siRNA inhibition of angiogenesis |
9175287, | Jul 12 2001 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
9175289, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | Reduced size self-delivering RNAi compounds |
9181551, | Feb 20 2002 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
9187757, | Jun 05 2009 | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC | Isolation and targeted suppression of lignin biosynthetic genes |
9193753, | Mar 30 2000 | University of Massachusetts; Whitehead Institute for Biomedical Research; Massachusetts Institute of Technology; Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | RNA sequence-specific mediators of RNA interference |
9200276, | Jun 01 2009 | HALO-BIO RNAI THERAPEUTICS, INC | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
9217129, | Feb 09 2007 | Massachusetts Institute of Technology; MASSACHUSETS INSTITUTE OF TECHNOLOGY | Oscillating cell culture bioreactor |
9222092, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
9233072, | Oct 12 2008 | Massachusetts Institute of Technology; The Brigham and Women's Hosptial, Inc.; President and Fellows of Harvard College | Adjuvant incorporation in immunonanotherapeutics |
9243246, | Aug 24 2010 | Sirna Therapeutics, Inc | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
9249414, | Jan 07 2010 | Quark Pharmaceuticals, Inc. | Oligonucleotide compounds comprising non-nucleotide overhangs |
9259475, | Apr 15 2011 | MOLECULAR TRANSFER, INC | Agents for improved delivery of nucleic acids to eukaryotic cells |
9260471, | Oct 29 2010 | Sirna Therapeutics, Inc | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
9267145, | May 03 2002 | Duke University | Method of regulating gene expression |
9267937, | Dec 15 2005 | Massachusetts Institute of Technology | System for screening particles |
9273312, | Sep 19 2007 | Applied Biosystems, LLC | SiRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAi, and stabilized forms thereof |
9284551, | Sep 19 2007 | Applied Biosystems, LLC | RNAi sequence-independent modification formats, and stabilized forms thereof |
9297009, | May 22 2007 | Arcturus Therapeutics, Inc. | UNA oligomers targeting micro-RNA for therapeutics |
9297010, | Mar 21 2003 | ROCHE INNOVATION CENTER COPENHAGEN A S | Short interfering RNA (siRNA) analogues |
9303259, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | RNA interference in skin indications |
9303260, | May 22 2007 | Arcturus Therapeutics, Inc. | UNA duplex oligomers for therapeutics |
9308280, | Oct 12 2008 | Massachusetts Institute of Technology; President and Fellows of Harvard College; The Brigham and Women's Hospital, Inc. | Targeting of antigen presenting cells with immunonanotherapeutics |
9315808, | Feb 13 2008 | BIANOSCIENCE GMBH | Cell-specifically effective molecules on the basis of siRNA and application kits for the production thereof and use thereof |
9333179, | Apr 04 2007 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Amphiphilic compound assisted nanoparticles for targeted delivery |
9340786, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | RNA interference in dermal and fibrotic indications |
9340789, | Dec 03 2008 | ARCTURUS THERAPEUTICS, INC | UNA oligomer structures for therapeutic agents |
9347060, | Feb 15 2007 | BIANOSCIENCE GMBH | Biologically active molecules, particularly based on PNA and siRNA, method for the cell-specific activation thereof, and application kit to be administered |
9353369, | Jan 14 2010 | BIANOSCIENCE GMBH | Biologically active molecules for influencing virus-, bacteria-, parasite-infected cells and/or tumor cells and method for the use thereof |
9365852, | May 08 2008 | MIRNA THERAPEUTICS, INC. | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
9381477, | Jun 23 2006 | Massachusetts Institute of Technology | Microfluidic synthesis of organic nanoparticles |
9387262, | Dec 27 2004 | Silence Therapeutics GMBH | Coated lipid complexes and their use |
9408832, | Mar 14 2012 | University of Central Florida Research Foundation, Inc | LIM kinasemodulating agents for neurofibromatoses therapy and methods for screening for same |
9433684, | Aug 19 2008 | Nektar Therapeutics | Conjugates of small-interfering nucleic acids |
9439859, | Oct 12 2008 | Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc.; Presidents and Fellows of Harvard College | Adjuvant incorporation in immunoanotherapeutics |
9447414, | Nov 12 2004 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
9474717, | Oct 12 2007 | IMMUNE DISEASE INSTITUTE, INC | Vaccine nanotechnology |
9492400, | Nov 04 2004 | THE BRIGHAM AND WOMEN S HOSPITAL, INC | Coated controlled release polymer particles as efficient oral delivery vehicles for biopharmaceuticals |
9493771, | May 02 2007 | Novartis AG | Short interfering ribonucleic acid (siRNA) for oral administration |
9493774, | Jan 05 2009 | PHIO PHARMACEUTICALS CORP | Inhibition of PCSK9 through RNAi |
9505867, | May 31 2005 | Ecole Polytechnique Federale de Lausanne | Triblock copolymers for cytoplasmic delivery of gene-based drugs |
9506061, | Nov 12 2004 | Asuragen, Inc. | Methods and compositions involving miRNA and miRNA inhibitor molecules |
9526702, | Oct 12 2007 | IMMUNE DISEASE INSTITUTE, INC | Vaccine nanotechnology |
9528121, | Feb 20 2007 | MONSANTO TECHNOLOGY LLC | Invertebrate microRNAs |
9539210, | Oct 12 2007 | IMMUNE DISEASE INSTITUTE, INC | Vaccine nanotechnology |
9540645, | May 08 2008 | The John Hopkins University; Asuragen, Inc. | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
9592250, | Feb 01 2002 | Life Technologies Corporation | Double-stranded oligonucleotides |
9611478, | Feb 03 2011 | MIRNA THERAPEUTICS, INC. | Synthetic mimics of miR-124 |
9642872, | Sep 30 2010 | University of Zurich | Treatment of B-cell lymphoma with microRNA |
9644241, | Sep 13 2011 | REDPATH EQUITYHOLDER REPRESENTATIVE, LLC | Methods and compositions involving miR-135B for distinguishing pancreatic cancer from benign pancreatic disease |
9650635, | Jun 04 2004 | University of Geneva | Pharmaceutical compositions comprising small interfering RNA inhibitors of NOX3 |
9655977, | Aug 31 2012 | The General Hospital Corporation | Biotin complexes for treatment and diagnosis of alzheimer's disease |
9657294, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
9662348, | Oct 14 2009 | GREENLIGHT BIOSCIENCES, INC | Compositions for controlling Varroa mites in bees |
9688812, | May 15 2006 | Massachusetts Institute of Technology; The Brigham and Women's Hospital, Inc. | Polymers for functional particles |
9695423, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
9700622, | Jul 11 2006 | PCI Biotech AS | Method for introducing siRNA into cells by photochemical internalisation |
9701960, | Nov 26 2009 | Quark Pharmaceuticals, Inc. | siRNA compounds comprising terminal substitutions |
9732344, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
9738894, | Mar 21 2003 | Roche Innovation Center Copenhagen A/S | Short interfering RNA (siRNA) analogues |
9738899, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
9745574, | Feb 04 2009 | PHIO PHARMACEUTICALS CORP | RNA duplexes with single stranded phosphorothioate nucleotide regions for additional functionality |
9758784, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
9764031, | May 26 2010 | Selecta Biosciences, Inc. | Dose selection of adjuvanted synthetic nanocarriers |
9765359, | Apr 15 2011 | MOLECULAR TRANSFER, INC. | Agents for improved delivery of nucleic acids to eukaryotic cells |
9771583, | Sep 19 2007 | Applied Biosystems, LLC | siRNA sequence-independent modification formats for reducing off-target phenotypic effects in RNAI, and stabilized forms thereof |
9771588, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
9777275, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
9783802, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
9790501, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
9790505, | Aug 05 2002 | Silence Therapeutics GMBH | Interfering RNA molecules |
9796978, | Feb 01 2002 | Life Technologies Corporation | Oligonucleotide compositions with enhanced efficiency |
9827325, | Dec 10 2009 | Cedars-Sinai Medical Center | Drug delivery of temozolomide for systemic based treatment of cancer |
9845466, | Aug 24 2010 | SIRNA THERAPEUTICS, INC. | Single-stranded RNAi agents containing an internal, non-nucleic acid spacer |
9850485, | May 03 2002 | Duke University | Method of regulating gene expression |
9850487, | Jul 12 2001 | University of Massachusetts | In vivo production of small interfering RNAs that mediate gene silencing |
9856475, | Mar 25 2014 | ARCTURUS THERAPEUTICS, INC | Formulations for treating amyloidosis |
9856476, | May 03 2002 | Duke University | Method of regulating gene expression |
9856477, | Nov 13 2012 | LONZA SALES AG | Delivery of therapeutic agent |
9932579, | May 05 2009 | GREENLIGHT BIOSCIENCES, INC | Prevention and treatment of Nosema disease in bees |
9938530, | Sep 22 2008 | PHIO PHARMACEUTICALS CORP | RNA interference in skin indications |
9944929, | May 22 2007 | Arcturus Therapeutics, Inc. | UNA single stranded oligomers for therapeutics |
9957505, | Jun 01 2009 | HALO-BIO RNAI THERAPEUTICS, INC. | Polynucleotides for multivalent RNA interference, compositions and methods of use thereof |
9957517, | Feb 20 2002 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
9963702, | Mar 24 2010 | PHIO PHARMACEUTICALS CORP | RNA interference in dermal and fibrotic indications |
9970005, | Oct 29 2010 | SIRNA THERAPEUTICS, INC. | RNA interference mediated inhibition of gene expression using short interfering nucleic acids (siNA) |
9982259, | Mar 25 2014 | ARCTURUS THERAPEUTICS, INC | Transthyretin allele selective UNA oligomers for gene silencing |
RE49229, | Dec 26 2014 | Nitto Denko Corporation | Methods and compositions for treating malignant tumors associated with KRAS mutation |
Executed on | Assignor | Assignee | Conveyance | Frame | Reel | Doc |
Apr 27 2004 | Max-Planck-Gesellschaft zur Foerderung der Wissenschaften e.V. | (assignment on the face of the patent) | / | |||
Oct 20 2008 | LENDECKEL, WINFRIED | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 022240 | /0958 | |
Nov 06 2008 | ELBASHIR, SAYDA | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 022240 | /0958 | |
Nov 03 2009 | EUROPAEISCHES LABORATORIUM FUER MOLEKULARBIOLOGIE EMBL | MAX-PLANCK-GESELLSCHAFT ZUR FOERDERUNG DER WISSENSCHAFTEN E V | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 023486 | /0572 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | University of Massachusetts | CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V , PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 026622 | /0057 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | Whitehead Institute for Biomedical Research | CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V , PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 026622 | /0057 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | Massachusetts Institute of Technology | CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V , PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 026622 | /0057 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | University of Massachusetts | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 026583 | /0614 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | Whitehead Institute for Biomedical Research | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 026583 | /0614 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | Massachusetts Institute of Technology | ASSIGNMENT OF ASSIGNORS INTEREST SEE DOCUMENT FOR DETAILS | 026583 | /0614 | |
Mar 14 2011 | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V | CORRECTIVE ASSIGNMENT TO CORRECT THE OMISSION OF ASSIGNEE, MAX-PLANCK-GESELLSCHAFT ZUR FORDERUNG DER WISSENSCHAFTEN E V , PREVIOUSLY RECORDED ON REEL 026583 FRAME 0614 ASSIGNOR S HEREBY CONFIRMS THE ASSIGNMENT | 026622 | /0057 |
Date | Maintenance Fee Events |
Sep 17 2009 | ASPN: Payor Number Assigned. |
Nov 27 2009 | M1551: Payment of Maintenance Fee, 4th Year, Large Entity. |
Feb 03 2010 | ASPN: Payor Number Assigned. |
Feb 03 2010 | RMPN: Payer Number De-assigned. |
Dec 06 2013 | M1552: Payment of Maintenance Fee, 8th Year, Large Entity. |
Dec 06 2017 | M1553: Payment of Maintenance Fee, 12th Year, Large Entity. |
Date | Maintenance Schedule |
Jun 06 2009 | 4 years fee payment window open |
Dec 06 2009 | 6 months grace period start (w surcharge) |
Jun 06 2010 | patent expiry (for year 4) |
Jun 06 2012 | 2 years to revive unintentionally abandoned end. (for year 4) |
Jun 06 2013 | 8 years fee payment window open |
Dec 06 2013 | 6 months grace period start (w surcharge) |
Jun 06 2014 | patent expiry (for year 8) |
Jun 06 2016 | 2 years to revive unintentionally abandoned end. (for year 8) |
Jun 06 2017 | 12 years fee payment window open |
Dec 06 2017 | 6 months grace period start (w surcharge) |
Jun 06 2018 | patent expiry (for year 12) |
Jun 06 2020 | 2 years to revive unintentionally abandoned end. (for year 12) |